Document:

2015.06.30 EX 10.4

EXHIBIT 10.4

TETRA TECHNOLOGIES, INC.

SECOND AMENDED AND RESTATED
2011 LONG TERM INCENTIVE COMPENSATION PLAN

TETRA TECHNOLOGIES, INC.

SECOND AMENDED AND RESTATED 
2011 LONG TERM INCENTIVE COMPENSATION PLAN

Table of Contents

	
			
	ARTICLE I     INTRODUCTION
	1
	

	     1.1  Purpose
	1
	

	     1.2  Definitions
	1
	

	     1.3  Shares Subject to the Plan

	5
	

	     1.4  Administration of the Plan
	6
	

	     1.5  Granting of Awards to Participants
	7
	

	     1.6  Leave of Absence
	7
	

	     1.7  Term of Plan
	7
	

	     1.8  Amendment and Discontinuance of the Plan
	8
	

	 
	 

	ARTICLE II     NONQUALIFIED OPTIONS
	8
	

	     2.1  Eligibility
	8
	

	     2.2  Exercise Price
	8
	

	     2.3  Terms and Conditions of Nonqualified Options
	8
	

	     2.4  Option Repricing
	10
	

	     2.5  Vesting
	10
	

	 
	 

	ARTICLE III     INCENTIVE OPTIONS
	10
	

	     3.1  Eligibility
	10
	

	     3.2  Exercise Price
	10
	

	     3.3  Dollar Limitation
	10
	

	     3.4  10% Stockholder
	11
	

	     3.5  Incentive Options Not Transferable
	11
	

	     3.6  Compliance with Code Section 422
	11
	

	     3.7  Limitations on Exercise
	11
	

	 
	 

	ARTICLE IV     BONUS STOCK
	11
	

	 
	 

	ARTICLE V     STOCK APPRECIATION RIGHTS
	11
	

	     5.1  Eligibility
	11
	

	     5.2  Repricing
	12
	

	     5.3  Vesting
	12
	

	 
	 

	ARTICLE VI     RESTRICTED STOCK
	12
	

	     6.1  Eligibility
	12
	

	     6.2  Restrictions, Restricted Period and Vesting
	12
	

	     6.3  Forfeiture of Restricted Stock
	13
	

	     6.4  Delivery of Shares of Common Stock
	13
	

	 
	 

	ARTICLE VII     PERFORMANCE AWARDS
	13
	

	     7.1  Performance Awards
	13
	

	
			
	     7.2  Performance Goals
	14
	

	 
	 

	ARTICLE VIII     CERTAIN PROVISIONS APPLICABLE TO ALL AWARDS
	15
	

	     8.1  General
	15
	

	     8.2  Stand-Alone, Additional and Substitute Awards
	16
	

	     8.3  Term of Awards
	17
	

	     8.4  Form and Timing of Payment Under Awards; Deferrals
	17
	

	     8.5  Vested and Unvested Awards
	18
	

	     8.6  Exemptions from Section 16(b) Liability
	18
	

	     8.7  Transferability
	18
	

	     8.8  Rights as a Stockholder
	19
	

	     8.9  Listing and Registration of Shares of Common Stock
	19
	

	     8.10  Termination of Employment, Death, Disability and Retirement
	19
	

	     8.11  Change in Control
	21
	

	     8.12  Clawback/Recoupment Policy
	22
	

	 
	 

	ARTICLE IX     WITHHOLDING FOR TAXES
	22
	

	 
	 

	ARTICLE X      MISCELLANEOUS
	23
	

	     10.1  No Rights to Awards or Uniformity Among Awards
	23
	

	     10.2  Conflicts with Plan
	23
	

	     10.3  No Right to Employment
	23
	

	     10.4  Governing Law
	23
	

	     10.5  Gender, Tense and Headings
	23
	

	     10.6  Severability
	23
	

	     10.7  Stockholder Agreements
	23
	

	     10.8  Funding
	23
	

	     10.9  No Guarantee of Tax Consequences
	23
	

TETRA TECHNOLOGIES, INC.
SECOND AMENDED AND RESTATED
2011 LONG TERM INCENTIVE COMPENSATION PLAN

ARTICLE I
INTRODUCTION

1.1    Purpose. This TETRA Technologies, Inc. Second Amended and Restated 2011 Long Term Incentive Compensation Plan (the Plan) amends and restates the TETRA Technologies, Inc. 2011 Long Term Incentive Compensation Plan (as previously amended and restated, the Original Plan) and is intended to promote the interests of TETRA Technologies, Inc., a Delaware corporation, (the Company) and its stockholders by encouraging Employees, Consultants and Non-Employee Directors of the Company or its Affiliates (as defined below) to acquire or increase their equity interests in the Company, thereby giving them an added incentive to work toward the continued growth and success of the Company, and to encourage them to remain with and devote their best efforts to the business of the Company thereby advancing the interests of the Company and its stockholders. The Board of Directors of the Company (the Board) also contemplates that through the Plan, the Company and its Affiliates will be better able to compete for the services of the individuals needed for the continued growth and success of the Company. The Plan provides for payment of various forms of incentive compensation and accordingly is not intended to be a plan that is subject to the Employee Retirement Income Security Act of 1974, as amended, and shall be administered accordingly. 

1.2    Definitions. As used in the Plan, the following terms shall have the meanings set forth below:

Affiliate means (i) any entity in which the Company, directly or indirectly, owns 10% or more of the combined voting power, as determined by the Committee, (ii) any “parent corporation” of the Company (as defined in Section 424(e) of the Code), (iii) any “subsidiary corporation” of any such parent corporation (as defined in Section 424(f) of the Code) of the Company and (iv) any trades or businesses, whether or not incorporated which are members of a controlled group or are under common control (as defined in Sections 414(b) or (c) of the Code) with the Company; provided, that, for the purpose of issuing Options or Stock Appreciation Rights, “Affiliate” means any corporation or other entity in a chain of corporations and/or other entities in which the Company has a “controlling interest” within the meaning of Treas. Reg. § 1.414(c)-2(b)(2)(i), but using the threshold of 50% ownership wherever 80% appears.

Awards means, collectively, Options, Bonus Stock, Stock Appreciation Rights, Restricted Stock or Performance Awards.
    
Board means the board of directors of the Company described in Section 1.1 of the Plan. 

Bonus Stock means Common Stock described in Article IV of the Plan.

Change in Control shall be deemed to have occurred upon any of the following events:

(i) any “person” (as defined in Section 3(a)(9) of the Exchange Act, and as modified in Section 13(d) and 14(d) of the Exchange Act) other than (A) the Company or any of its majority subsidiaries, (B) any employee benefit plan of the Company or any of its subsidiaries, (C) or any Affiliate (as determined immediately prior to such event), (D) a company owned, directly or indirectly, by stockholders of the Company in substantially the same proportions as their ownership of the Company, or (E) an underwriter temporarily holding securities pursuant to an offering of such securities (a Person), becomes the 

1

“beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing more than 50% of the shares of voting stock of the Company then outstanding; 

(ii) the consummation of any merger, reorganization, business combination or consolidation of the Company or one of its subsidiaries with or into any other company, other than a merger, reorganization, business combination or consolidation which would result in the holders of the voting securities of the Company outstanding immediately prior thereto holding securities which represent immediately after such merger, reorganization, business combination or consolidation more than 50% of the combined voting power of the voting securities of the Company or the surviving company or the parent of such surviving company;

(iii) the consummation of a sale or disposition by the Company of all or substantially all of the Company’s assets, other than a sale or disposition if the holders of the voting securities of the Company outstanding immediately prior thereto hold securities immediately thereafter which represent more than 50% of the combined voting power of the voting securities of the acquiror, or parent of the acquiror, of such assets;

(iv) the stockholders of the Company approve a plan of complete liquidation or dissolution of the Company; or

(v) individuals who, as of the Effective Date, constitute the Board (the Incumbent Board) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the Effective Date whose election, or nomination for election by the Company’s stockholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board, shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an election contest with respect to the election or removal of directors or other solicitation of proxies or consents by or on behalf of a person other than the Board.

Notwithstanding the foregoing, however, in any circumstance or transaction in which compensation resulting from or in respect of an Award would be subject to the income tax under Section 409A of the Code if the foregoing definition of “Change in Control” were to apply, but would not be so subject if the term “Change in Control” were defined herein to mean a “change in control event” within the meaning of Treas. Reg. § 1.409A-3(i)(5), then “Change in Control” shall mean a transaction, event or circumstance that constitutes a Change in Control as defined above and that also constitutes a “change in control event” within the meaning of Treas. Reg. § 1.409A-3(i)(5), but only to the extent necessary to prevent such compensation from becoming subject to the income tax under Section 409A of the Code.

Code means the Internal Revenue Code of 1986, as amended from time to time, and the rules and regulations thereunder.

Committee means the Compensation Committee of the Board which shall consist of not less than three members of the Board, each of whom shall qualify as a “non-employee director” (as that term is defined in Rule 16b-3 of the General Rules and Regulations under the Exchange Act) appointed by and serving at the pleasure of the Board to administer the Plan or, if none, the Board; provided however, that with respect to any Award granted to a Covered Employee which is intended to be “performance-based compensation” as described in Section 162(m)(4)(C) of the Code, the Committee shall consist solely of two or more “outside directors” as described in Section 162(m)(4)(C)(i) of the Code. 

Common Stock means the common stock, $0.01 par value per share of the Company.

2

Company means the corporation described in Section 1.1 of the Plan or any successor thereto which assumes and continues the Plan.

Consultant means any individual, other than a Director or an Employee, who renders consulting or advisory services to the Company or an Affiliate, provided such services are not in connection with the offer or sale of securities in a capital raising transaction.

Covered Employee means any of the Chief Executive Officer of the Company and the three highest paid officers of the Company other than the Chief Executive Officer or the Chief Financial Officer as described in Section 162(m)(3) of the Code or any individual Consultant, Director or other Employee, or class of Consultants, Directors or Employees, who the Committee specifies in an Award shall be treated as a Covered Employee.

Disability means an inability to perform the Participant’s material services for the Company for a period of 90 consecutive days or a total of 180 days, during any 365-day period, in either case as a result of incapacity due to mental or physical illness, which is determined to be total and permanent. A determination of Disability shall be made by a physician satisfactory to both the Participant (or his guardian) and the Company, provided that if the Participant (or his guardian) and the Company do not agree on a physician, the Participant and the Company shall each select a physician and these two together shall select a third physician, whose determination as to Disability shall be final, binding and conclusive with respect to all parties. Notwithstanding the above, eligibility for disability benefits under any policy for long-term disability benefits provided to the Participant by the Company shall conclusively establish the Participant’s disability. In the case of any Award that is or becomes subject to Section 409A of the Code, “Disability” means a condition that meets the requirements of Treas. Reg. § 1.409A-3(i)(4).

Effective Date means May 3, 2011, the date on which the Original Plan was initially approved by stockholders of the Company. The provisions of the Original Plan, as amended from time to time including, without limitation, the Plan, shall be applicable to all Awards granted on or after the Effective Date. 

Employee means any employee of the Company or an Affiliate.

Employment means any period in which a Participant is an Employee of the Company or an Affiliate. 

Exchange Act means the Securities Exchange Act of 1934, as amended.

Fair Market Value or FMV Per Share means, as of any given date, the closing price per share on the principal exchange or over-the-counter market on which such shares are trading, if any, or as reported on any composite index which includes such principal exchange, or if no trade of the Common Stock shall have been reported for such date, the closing price quoted on such exchange or market for the immediately preceding date on which such shares were traded. The term “closing price” on any given day shall mean (i) if the shares of Common Stock are listed or admitted for trading on a national securities exchange, the last reported sales price on such day, or (ii) if the shares of Common Stock are not listed or admitted for trading on a national securities exchange, the last transaction price on such day of the shares of Common Stock on the Nasdaq Market, Inc. (“NASDAQ”). If shares of the Common Stock are not listed or admitted to trading on any exchange, over-the-counter market or any similar organization on any given day, the FMV Per Share shall be determined by the Committee in good faith using any fair and reasonable means selected in its discretion.

Full Value Award means an Award that is settled by the issuance of shares of common stock, other than an Option or a Stock Appreciation Right.  

3

Incentive Option means any option that satisfies the requirements of Code Section 422 and is granted pursuant to Article III of the Plan.

Incumbent Board means the Board described in paragraph (v) of the definition of Change in Control under Section 1.2 of the Plan.

Non-Employee Director means a person who is a member of the Board but who is neither an Employee nor a Consultant of the Company or any Affiliate.

Nonqualified Option means an option not intended to satisfy the requirements of Code Section 422 and which is granted pursuant to Article II of the Plan.

Option means an option to acquire Common Stock granted pursuant to the provisions of the Plan, and refers to either an Incentive Stock Option or a Nonqualified Stock Option, or both, as applicable.

Option Expiration Date means the date determined by the Committee which shall not be more than ten years after the date of grant of an Option.

Optionee means a Participant who has received or will receive an Option.

Original Plan has the meaning set forth in the definition of Effective Date under Section 1.2 of the Plan.

Participant means any Non-Employee Director, Employee or Consultant granted an Award under the Plan.

Performance Award means an Award granted pursuant to Article VII of the Plan which, if earned, will afford the Participant the right to receive shares of Common Stock, cash or any combination thereof as determined by the Committee. 

Plan means the plan described in Section 1.1 of the Plan and set forth in this document, as amended from time to time.

Restricted Period means the period established by the Committee with respect to an Award during which the Award either remains subject to forfeiture or is not exercisable by the Participant. 

Restricted Stock means one or more shares of Common Stock prior to the lapse of restrictions thereon, granted under Article VI of the Plan.

Retirement means termination of Employment of an Employee or termination of service of a Non-Employee Director or Consultant, in each case under circumstances as shall constitute retirement as determined by the Committee.  

Securities Act means the Securities Act of 1933, as amended. 

Spread means the amount determined pursuant to Section 5.1(a) of the Plan.

Stock Appreciation Right means an Award granted pursuant to Article V of the Plan.

    

4

1.3    Shares Subject to the Plan. Subject to adjustment as provided in this Plan, the maximum number of shares of Common Stock that may be covered by Awards granted under the Plan shall be 5,600,000 shares, and of that number the maximum aggregate number of shares of Common Stock that may be issued under the Plan through Options is 5,600,000 shares, all or any portion of which may be Incentive Options. Solely for the purposes of implementing the limitation of the immediately preceding sentence, an Award of an Option or a Stock Appreciation Right in respect of one share of Common Stock shall be deemed to be an Award of one share of Common Stock on the date of grant. An Award of a share of Bonus Stock or Restricted Stock shall be deemed to be an Award of 1.38 shares of Common Stock for every one share granted on the date of grant. With respect to any Performance Award to be settled in shares of Common Stock, the value of the maximum benefit that may be paid under the Performance Award shall be divided by the FMV Per Share of Common Stock as of the date of grant of the Performance Award and each share resulting from such computation shall be deemed to be an Award of 1.38 shares of Common Stock for purposes of implementing the limitation on shares set forth in the first sentence of this Section 1.3. If the number of shares of Common Stock issued in settlement of the Performance Award exceeds the number determined to be issued on the date of grant in accordance with the preceding sentence, each such additional share of Common Stock issued shall be deemed to be an Award of 1.38 shares of Common Stock for the purposes of implementing the limitation on shares set forth in the first sentence of this Section 1.3. In addition, during any calendar year, the maximum number of shares of Common Stock underlying Awards (other than Performance Awards) granted to any one Participant in such calendar year shall not exceed 400,000 shares. The maximum amount of compensation (whether denominated or payable in shares of Common Stock, cash, other Awards or other property) that any one Participant may receive in any calendar year in respect of Performance Awards may not exceed, in the aggregate, $2,000,000.  

Notwithstanding the above, in the event that at any time after the Effective Date the outstanding shares of Common Stock are changed into or exchanged for a different number or kind of shares or other securities of the Company by reason of a merger, consolidation, recapitalization, reclassification, stock split, stock dividend, combination of shares or the like, the aggregate number and class of securities available under the Plan shall, subject to any required action by the stockholders of the Company, be ratably adjusted by the Committee. Upon the occurrence of any of the events described in the immediately preceding sentence, in order to ensure that after such event the shares of Common Stock subject to the Plan and each Participant’s proportionate interest shall be maintained substantially as before the occurrence of such event, the Committee shall, in such manner as it may deem equitable, adjust (i) the number of shares of Common Stock with respect to which Awards may be granted under the Plan, (ii) the maximum number of shares of Common Stock that may be covered by Awards to any single individual during any calendar year, (iii) the number of shares of Common Stock subject to outstanding Awards, (iv) the grant or exercise price with respect to an Award, and (v) the ratio for the determination of Full Value Awards as set forth above in this Section 1.3; provided, however, that (A) with respect to Incentive Stock Options, such adjustment shall be made in accordance with Section 424 of the Code, and (B) with respect to all Awards, such adjustment shall be effected in a manner, along with any other changes or adjustments as the Committee shall deem appropriate, to ensure (1) that any Award that is not subject to, or that complies with, Section 409A of the Code shall continue to be not subject to, or continue to comply with Section 409A of the Code, (2) any Award that was intended to comply with the exemption for “performance-based compensation” under Section 162(m) of the Code shall continue to so comply, and (3) the changes and adjustments do not result in any material reduction in the benefit of the Award to the Participant without the consent of the Participant. 

In the event the number of shares to be delivered upon the exercise or payment of any Award granted under the Plan is reduced for any reason other than the withholding of shares for payment of taxes or exercise price, or in the event any Award (or portion thereof) granted under the Plan can no longer under any circumstances be exercised or paid, the number of shares no longer subject to such Award shall thereupon be released from such Award and shall thereafter be available for the grant of additional Awards 

5

under the Plan in the same amount as such shares were counted against the limit set forth in the first paragraph of this Section 1.3. If any Performance Award granted under this Plan may only be settled in cash, such Award shall not be counted against the maximum number of shares that may be covered by Awards granted under the Plan as set forth in the first paragraph of this Section 1.3. Shares of Common Stock that cease to be subject to an Award because of the exercise of the Award, or the vesting of a Restricted Stock Award or similar Award, shall no longer be subject to any further grant under the Plan. Notwithstanding anything to the contrary, (i) shares of Common Stock that are tendered, whether by physical delivery or by attestation, to the Company by a Participant or withheld from any Award by the Company as full or partial payment of the exercise price or purchase price of any Award shall not be added back to the maximum share limitations described above or thereafter be made available under the Plan for the grant of additional Awards; (ii) shares that are withheld from any Award by the Company in payment of any applicable tax withholding obligation in connection with the exercise, vesting or earning of any Award shall not be added back to the maximum share limitations described above or thereafter made available under the Plan for the grant of additional awards; and (iii) with respect to Stock Appreciation Rights, when a Stock Appreciation Right is exercised, the shares of Common Stock subject to such Stock Appreciation Right shall be counted against the shares available for issuance under the Plan as one share of Common Stock for every share subject thereto, regardless of the number of shares of Common Stock used to settle the Stock Appreciation Right upon exercise. Shares issued pursuant to the Plan (i) may be treasury shares, authorized but unissued shares or, if applicable, shares acquired in the open market and (ii) shall be fully paid and nonassessable. No fractional shares shall be issued under the Plan; payment for any fractional shares shall be made in cash.

Notwithstanding anything in the Plan to the contrary, the Committee may grant or amend Full Value Awards covering up to ten percent (10%) of the shares of Common Stock available for issuance pursuant to this Section 1.3, and awards of Stock Options and Stock Appreciation Rights covering up to 15% of the shares of Common Stock available for issuance pursuant to this Section 1.3, without regard to the minimum vesting requirements of Article IV and Sections 2.5, 5.3 and  6.2(b) of the Plan. 

1.4    Administration of the Plan. 

(a)    The Plan shall be administered by the Committee. Subject to the provisions of the Plan, the Committee shall (i) select the Employees, Consultants and Non-Employee Directors to whom Awards may be granted hereunder, (ii) determine the type or types of Awards to be made, (iii) determine the size or number of shares to be subject to an Award, (iv) determine the terms and conditions of any Award, consistent with the terms of the Plan, which terms may include the time or times when Awards may be exercised (which may be based on performance criteria), any provision regarding the acceleration of vesting or waiver of forfeiture restrictions, and any other condition or limitation regarding an Award, based on such factors as the Committee, in its sole discretion, will determine, (v) determine, as to all or part of any Award as to any Participant, at the time the Award is granted or thereafter, whether, to the extent, and under what circumstances an Award may be vested, canceled, forfeited or surrendered (including the acceleration of the exercisability or vesting of, or a waiver of the terms and conditions applicable to, any Award), in connection with the Participant’s death, Disability, Retirement, a Change in Control, a termination of the Participant’s Employment or termination of the Participant’s service following a Change in Control, or such other circumstances as may be determined by the Committee, for any reason at any time; (vi) modify or amend each Award, including the discretionary acceleration of exercisability or vesting, the waiver of forfeiture restrictions or other terms and conditions applicable to an Award, and the authority to extend the post-termination exercisability period of Awards under the conditions set forth in the Plan, provided that any such extension may not exceed the expiration date set forth in the Award, (vii) interpret the Plan and all Awards under the Plan, (viii) make, amend and rescind such rules as it deems necessary for the proper administration of the Plan, (ix) make all other determinations necessary or advisable for the administration of the Plan and 

6

(x) correct any defect or supply any omission or reconcile any inconsistency in the Plan or in any Award under the Plan in the manner and to the extent that the Committee deems desirable to effectuate the Plan. Any action taken or determination made by the Committee pursuant to this and the other paragraphs of the Plan shall be final, binding and conclusive on all affected persons, including the Company; any Affiliate; any grantee, holder or beneficiary of an Award; any stockholder; and any Employee, Consultant or Non-Employee Director. No member of the Board or of the Committee shall be liable for any action or determination made in good faith with respect to the Plan or any Award granted hereunder and the members of the Board and the Committee shall be entitled to indemnification and reimbursement by the Company and its Affiliates in respect of any claim, loss, damage or expense (including legal fees) arising therefrom to the full extent permitted by law.

(b)    Subject to the following provisions, the Committee may from time to time delegate, to the extent permitted by law, some or all of its authority and powers under the Plan, including the authority to grant Awards under the Plan, to a committee consisting of one or more members of the Board; provided, however, that the Committee may not delegate its authority (i) to make Awards to any Participant (A) who is, or is expected to be, a Covered Employee, or (B) who is, or is expected to become, subject to Section 16 of the Exchange Act, (ii) to interpret the Plan or any Award, or (iii) to amend any Award or to accelerate the vesting or lapse of any restrictions on any Award.  Any delegation hereunder shall be subject to such other restrictions and limitations that the Committee specifies at the time of such delegation or thereafter.  Nothing in the Plan shall be construed as obligating the Committee to delegate authority as herein provided and the Committee may at any time rescind the authority delegated hereunder.  Any action undertaken by such Board committee in accordance with the Committee’s delegation of authority shall have the same force and effect as if undertaken directly by the Committee, and any reference in the Plan shall, to the extent consistent with the terms and limitations of such delegation, be deemed to include the Board committee to whom such authority has been delegated.  

1.5    Granting of Awards to Participants. The Committee shall have the authority to grant, prior to the expiration date of the Plan, Awards to such Employees, Consultants and Non-Employee Directors as may be selected by it subject to the terms and conditions hereinafter set forth in the Plan. In selecting the persons to receive Awards, including the type and size of the Award, the Committee may consider the contribution the recipient has made and/or may make to the growth of the Company or its Affiliates and any other factors that it may deem relevant. No member of the Committee shall vote or act upon any matter relating solely to himself. Grants of Awards to members of the Committee must be ratified by the Board. In no event shall any Employee, Consultant or Non-Employee Director, nor his or its legal representatives, heirs, legatees, distributees or successors have any right to participate in the Plan except to such extent, if any, as permitted under the Plan and as the Committee may determine.

1.6    Leave of Absence. If an Employee is on military, sick leave or other bona fide leave of absence, such person shall be considered an “Employee” for purposes of an outstanding Award during the period of such leave provided it does not exceed 90 days (or such longer period as may be determined by the Committee in its sole discretion), or, if longer, so long as the person’s right to reemployment is guaranteed either by statute or by contract. If the period of leave exceeds 90 days (or such longer period as may be determined by the Committee in its sole discretion), the employment relationship shall be deemed to have terminated on the 91st day (or the first day immediately following any period of leave in excess of 90 days as approved by the Committee) of such leave, unless the person’s right to reemployment is guaranteed by statute or contract.

    

7

1.7    Term of Plan. If not sooner terminated under the provisions of Section 1.9, the Plan shall terminate upon, and no further Awards shall be made, after February 16, 2021; provided, however, that the termination of the Plan on such date will not affect the validity of any Award outstanding on the date of termination, which shall continue to be governed by the applicable terms and conditions of the Plan.

1.8    Amendment and Discontinuance of the Plan. The Board may amend, suspend or terminate the Plan at any time without prior notice to or consent of any person; provided, however, subject to Section 8.11, no amendment, suspension or termination of the Plan may without the consent of the holder of an Award terminate such Award or adversely affect such person’s rights with respect to such Award in any material respect; and provided further, however, that no amendment of the Plan shall be effective prior to its approval by the stockholders of the Company to the extent that (i) it would contravene the requirements of Section 2.4 or Section 5.2 of the Plan or (ii) such approval is required by (A) applicable legal requirements, (B) the requirements of any securities exchange on which the Company’s stock may be listed or (C) the requirements of the Nasdaq Stock Market, Inc. on which the Company’s stock may be listed. Notwithstanding the foregoing, the Board may amend the Plan in such manner as it deems necessary in order to permit Awards to meet the requirements of the Code or other applicable laws, or to prevent adverse tax consequences to the Participants.

ARTICLE II
NONQUALIFIED OPTIONS

2.1    Eligibility. The Committee may grant Nonqualified Options to purchase the Common Stock to any Employee, Consultant and Non-Employee Director according to the terms set forth below. Each Nonqualified Option granted under the Plan shall be evidenced by a written agreement between the Company and the individual to whom Nonqualified Options were granted in such form as the Committee shall provide.

2.2    Exercise Price. The exercise price to be paid for each share of Common Stock deliverable upon exercise of each Nonqualified Option granted under this Article II shall not be less than one hundred percent (100%) of the FMV Per Share as of the date of grant of such Nonqualified Option. The exercise price for each Nonqualified Option granted under Article II shall be subject to adjustment as provided in Section 2.3(d) of the Plan.

2.3    Terms and Conditions of Nonqualified Options. Nonqualified Options shall be in such form as the Committee may from time to time approve, shall be subject to the following terms and conditions and may contain such additional terms and conditions, not inconsistent with this Article II, as the Committee shall deem desirable:

(a)    Option Period and Conditions and Limitations on Exercise. No Nonqualified Option shall be exercisable later than the Option Expiration Date. To the extent not prohibited by other provisions of the Plan, each Nonqualified Option shall be exercisable at such time or times as the Committee in its discretion may determine.

(b)    Manner of Exercise. In order to exercise a Nonqualified Option, the person or persons entitled to exercise it shall deliver to the Company payment in full for (i) the shares being purchased and (ii) unless other arrangements have been made with the Committee, any required withholding taxes. The payment of the exercise price for each Nonqualified Option shall either be (i) in cash or by check payable and acceptable to the Company, (ii) with the consent of the Committee, by tendering to the Company shares of Common Stock owned by the person for more than six months having an aggregate Fair Market Value as of the date of exercise that is not greater than the full exercise price for the shares with respect to which the Nonqualified Option is being exercised and by paying any remaining amount of the exercise price as provided in (i) above, or (iii) with the consent of the Committee and compliance with such instructions as the Committee may 

8

specify, by delivering to the Company and to a broker a properly executed exercise notice and irrevocable instructions to such broker to deliver to the Company cash or a check payable and acceptable to the Company to pay the exercise price and any applicable withholding taxes. Upon receipt of the cash or check from the broker, the Company will deliver to the broker the shares for which the Nonqualified Option is exercised. In the event that the person elects to make payment as allowed under clause (ii) above, the Committee may, upon confirming that the Optionee owns the number of additional shares being tendered, authorize the issuance of a new certificate for the number of shares being acquired pursuant to the exercise of the Nonqualified Option less the number of shares being tendered upon the exercise and return to the person (or not require surrender of) the certificate for the shares being tendered upon the exercise. The date of sale of the shares by the broker pursuant to a cashless exercise under (iii) above shall be the date of exercise of the Nonqualified Option. If the Committee so requires, such person or persons shall also deliver a written representation that all shares being purchased are being acquired for investment and not with a view to, or for resale in connection with, any distribution of such shares.

(c)    Nonqualified Options not Transferable. Except as provided below, no Nonqualified Option granted hereunder shall be transferable other than by (i) will or by the laws of descent and distribution or (ii) pursuant to a domestic relations order and, during the lifetime of the Participant to whom any such Nonqualified Option is granted, it shall be exercisable only by the Participant (or his guardian). Any attempt to transfer, assign, pledge, hypothecate or otherwise dispose of, or to subject to execution, attachment or similar process, any Nonqualified Option granted hereunder, or any right thereunder, contrary to the provisions hereof, shall be void and ineffective, shall give no right to the purported transferee, and shall, at the sole discretion of the Committee, result in forfeiture of the Nonqualified Option with respect to the shares involved in such attempt. With respect to a specific Nonqualified Option, in accordance with rules and procedures established by the Committee from time to time, the Participant (or his guardian) may transfer, for estate planning purposes, all or part of such Nonqualified Option to one or more immediate family members or related family trusts or partnerships or similar entities as determined by the Committee. Any Nonqualified Option that is transferred in accordance with the provisions of this Section may only be exercised by the person or persons who acquire a proprietary interest in the Nonqualified Options pursuant to the transfer.

     (d)    Adjustment of Nonqualified Options. In the event that at any time after the Effective Date the outstanding shares of Common Stock are changed into or exchanged for a different number or kind of shares or other securities of the Company by reason of merger, consolidation, recapitalization, reclassification, stock split, stock dividend, combination of shares or the like, proportionate adjustments shall be made as provided in Section 1.3.

(e)    Listing and Registration of Shares. Each Nonqualified Option shall be subject to the requirement that if at any time the Committee determines, in its discretion, that the listing, registration, or qualification of the shares subject to such Nonqualified Option under any securities exchange or under any state or federal law, or the consent or approval of any governmental regulatory body, is necessary or desirable as a condition of, or in connection with, the issue or purchase of shares thereunder, such Nonqualified Option may not be exercised in whole or in part unless such listing, registration, qualification, consent or approval shall have been effected or obtained and the same shall have been free of any conditions not acceptable to the Committee.

    

9

2.4    Option Repricing. With stockholder approval, the Committee may grant to holders of outstanding Nonqualified Options, in exchange for the surrender and cancellation of such Nonqualified Options, new Nonqualified Options having exercise prices lower (or higher with any required consent) than the exercise price provided in the Nonqualified Options so surrendered and cancelled and containing such other terms and conditions as the Committee may deem appropriate. Except as contemplated by Section 2.3(d), no Nonqualified Option may be amended to reduce the exercise price of the shares subject to such Nonqualified Option without prior stockholder approval. 

2.5    Vesting. See Section 8.10 of the Plan for provisions on vesting in connection with termination of a Participant’s Employment or termination of a Participant’s service. Also, see Section 8.11 of the Plan relating to vesting in connection with a Change in Control or a termination of Employment or termination of service following a Change in Control. Subject to the final paragraph of Section 1.3 of the Plan, no condition on vesting of a Nonqualified Option that is based upon continued employment or the passage of time shall provide for vesting in full of the Nonqualified Option more quickly than in pro rata installments over three years from the date of grant of the Award.

ARTICLE III
INCENTIVE OPTIONS

The terms specified in this Article III shall be applicable to all Incentive Options. Except as modified by the provisions of this Article III, all the provisions of Article II shall be applicable to Incentive Options. Options which are specifically designated as Nonqualified Options shall not be subject to the terms of this Article III.

3.1    Eligibility. Incentive Options may only be granted to Employees of the Company or its parent or subsidiary as defined in Sections 424(e) or (f) of the Code, as applicable, while each such entity is a “corporation” described in Section 7701(a)(3) of the Code and Treas. Reg. Section 1.421-1(i)(1).

3.2    Exercise Price. Subject to Section 3.4, the exercise price per share shall not be less than one hundred percent (100%) of the FMV Per Share as of the option date of grant.

3.3    Dollar Limitation. The aggregate Fair Market Value (determined as of the respective date or dates of grant) of shares of Common Stock for which one or more options granted to any Employee under the Plan (or any other option plan of the Company or any Affiliate which is a parent or subsidiary as defined in Code Sections 424(e) or (f), as applicable) may for the first time become exercisable as Incentive Options during any one (1) calendar year shall not exceed the sum of One Hundred Thousand Dollars ($100,000). To the extent the Employee holds two (2) or more such options which become exercisable for the first time in the same calendar year, the foregoing limitation on the exercisability of such options as Incentive Options shall be applied on the basis of the order in which such options are granted.

3.4    10% Stockholder. If any Employee to whom an Incentive Option is granted owns stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or any “parent corporation” of the Company (as defined in Section 424(e) of the Code) or any “subsidiary corporation” of the Company (as defined in Section 424(f) of the Code), then the exercise price per share shall not be less than one hundred ten percent (110%) of the FMV Per Share as of the date of grant and the option term shall not exceed five (5) years measured from the date of grant. For purposes of the immediately preceding sentence, the attribution rules under Section 424(d) of the Code shall apply for purposes of determining an Employee’s ownership.

3.5    Incentive Options Not Transferable. No Incentive Option granted hereunder (i) shall be transferable other than by will or by the laws of descent and distribution and (ii) except as permitted in 

10

regulations or other guidance issued under Section 422 of the Code, shall be exercisable during the Optionee’s lifetime by any person other than the Optionee (or his guardian).

3.6    Compliance With Code Section 422. All Options that are intended to be incentive stock options described in Code Section 422 shall be designated as such in the Option grant and in all respects shall be issued in compliance with Code Section 422.

3.7    Limitations on Exercise. Except as provided in Section 8.10(d), no Incentive Option shall be exercisable after the earlier of (i) three (3) months after the Optionee ceases to be an Employee for any reason other than death or Disability, or more than one (1) year after the Optionee ceases to be an Employee due to death or Disability, and (ii) the Option Expiration Date.

ARTICLE IV
BONUS STOCK

The Committee may, from time to time and subject to the provisions of the Plan including the limitation set forth in Section 1.3 of the Plan, grant shares of Bonus Stock to Employees, Consultants and Non-Employee Directors. Such grants of Bonus Stock shall be in consideration of performance of services by the Participant without additional consideration except as may be required by the Committee or pursuant to Article IX. Notwithstanding the foregoing, subject to the final paragraph of Section 1.3 of the Plan, , no condition on vesting of a Bonus Stock Award that is based upon achievement of specified performance goals shall be based on performance over a period of less than one year and no condition on vesting of a Bonus Stock Award that is based upon continued employment or the passage of time shall provide for vesting in full of the Bonus Stock Award more quickly than in pro rata installments over three years from the date of grant of the Bonus Stock Award.  

ARTICLE V
STOCK APPRECIATION RIGHTS

5.1    Eligibility. The Committee is authorized to grant Stock Appreciation Rights to Employees, Consultants and Non-Employee Directors on the following terms and conditions.

(a)    Right to Payment. A Stock Appreciation Right shall confer on the Participant to whom it is granted, upon exercise thereof, a right to receive shares of Common Stock, the value of which is equal to the excess of (A) the FMV Per Share on the date of exercise over (B) the deemed exercise price which shall be one hundred percent (100%) of the FMV Per Share as of the date of grant (the Spread) with respect to a specified number of shares of Common Stock. Notwithstanding the foregoing, the Committee may provide, in its sole discretion, that the Spread covered by a Stock Appreciation Right may not exceed a specified amount. The deemed exercise price for each Stock Appreciation Right granted under Article V shall be subject to adjustment as provided in Section 1.3 in the event that at any time after the Effective Date the outstanding shares of Common Stock are changed into or exchanged for a different number or kind of shares or other securities of the Company by reason of a merger, consolidation, recapitalization, reclassification, stock split, stock dividend, or a combination of shares or the like.

(b)    Terms. The Committee shall determine at the date of grant the time or times at which and the circumstances under which a Stock Appreciation Right may be exercised in whole or in part (including based on achievement of performance goals and/or future service requirements), the method of exercise, and any other terms and conditions of any Stock Appreciation Right; provided, however, a Stock Appreciation Right shall not be granted in tandem or in combination with any other Award if that would (i) cause application of Section 409A of the Code to the Award or (ii) result in adverse tax consequences under Section 409A of the Code should that code section apply to the Award.

11

5.2    Repricing. With stockholder approval, the Committee may grant to holders of outstanding Stock Appreciation Rights, in exchange for the surrender and cancellation of such Stock Appreciation Rights, new Stock Appreciation Rights having deemed exercise prices lower (or higher with any required consent) than the deemed exercise price provided in the Stock Appreciation Rights so surrendered and cancelled and containing such other terms and conditions as the Committee may deem appropriate. Except as contemplated by Section 1.3, no Stock Appreciation Right may be amended to reduce the deemed exercise price of the shares subject to such Stock Appreciation Right without prior stockholder approval.

5.3    Vesting. Subject to the final paragraph of Section 1.3 of the Plan, no condition on vesting of a Stock Appreciation Right that is based upon continued employment or the passage of time shall provide for vesting in full of the Stock Appreciation Right more quickly than in pro rata installments over three years from the date of grant of the Award.

ARTICLE VI
RESTRICTED STOCK

6.1    Eligibility. All Employees, Consultants and Non-Employee Directors shall be eligible for grants of Restricted Stock.

6.2    Restrictions, Restricted Period and Vesting.

(a)    The Restricted Stock shall be subject to such forfeiture restrictions (including, without limitation, limitations that qualify as a “substantial risk of forfeiture” within the meaning given to that term under Section 83 of the Code) and restrictions on transfer by the Participant and repurchase by the Company as the Committee, in its sole discretion, shall determine, including, without limitation, restrictions based on the achievement of specific performance goals (which may be based on one or more of the criteria set forth in Section 7.2(b)) and time-based restrictions or holding requirements or sale restrictions placed on the shares of Common Stock by the Company upon vesting of such Restricted Stock. Prior to the lapse of such restrictions the Participant shall not be permitted to transfer such shares. The Company shall have the right to repurchase or recover such shares for the amount of any cash paid therefor if (i) the Participant’s Employment with or service to the Company shall terminate prior to the lapse of such restrictions or (ii) the Restricted Stock is forfeited by the Participant pursuant to the terms of the Award. 

(b)    Vesting. See Section 8.10 of the Plan for provisions on vesting in connection with termination of a Participant’s Employment or service. Also, see Section 8.11 of the Plan relating to vesting in connection with a Change in Control or termination of a Participant’s Employment or termination of a Participant’s service following a Change in Control. Subject to the final paragraph of Section 1.3 of the Plan, no condition on vesting of a Restricted Stock Award that is based upon achievement of specified performance goals shall be based on performance over a period of less than one year and no condition on vesting of a Restricted Stock Award that is based upon continued employment or the passage of time shall provide for vesting in full of the Restricted Stock Award more quickly than in pro rata installments over three years from the date of grant of the Restricted Stock Award.  

(c)    Immediate Transfer Without Immediate Delivery of Restricted Stock. Each certificate representing Restricted Stock awarded under the Plan shall be registered in the name of the Participant and, during the Restricted Period shall be left on deposit with the Company, or in trust or escrow pursuant to an agreement satisfactory to the Committee, along with a stock power endorsed in blank until such time as the restrictions on transfer have lapsed. The grantee of Restricted Stock shall have all the rights of a stockholder with respect to such shares including the right to vote and the right to receive dividends or other distributions paid or made with respect to such shares; provided, however, the Committee may in the Award 

12

restrict the Participant’s right to dividends until the restrictions on the Restricted Stock lapse. Any certificate or certificates representing shares of Restricted Stock shall bear a legend similar to the following:

The shares represented by this certificate have been issued pursuant to the terms of the TETRA Technologies, Inc. Amended and Restated 2011 Long Term Incentive Compensation Plan and may not be sold, pledged, transferred, assigned or otherwise encumbered in any manner except as is set forth in the terms of the Award dated         , 20__.

6.3    Forfeiture of Restricted Stock. If, for any reason, the restrictions imposed by the Committee upon Restricted Stock are not satisfied at the end of the Restricted Period, any Restricted Stock remaining subject to such restrictions shall thereupon be forfeited by the Participant and reacquired by the Company.

6.4    Delivery of Shares of Common Stock. Pursuant to Section 8.5 of the Plan and subject to withholding requirements of Article IX of the Plan, at the expiration of the Restricted Period, a stock certificate evidencing the Restricted Stock (to the nearest full share) with respect to which the Restricted Period has expired shall be delivered without charge to the Participant, or his personal representative, free of all restrictions under the Plan. 

ARTICLE VII
PERFORMANCE AWARDS

7.1    Performance Awards. The Committee may grant Performance Awards based on performance goals as set forth in Section 7.2 measured over a performance period established pursuant to Section 7.2(c) of the Plan. The Committee may use any such business criteria and other measures of performance as set forth in Section 7.2 as it may deem appropriate in establishing any performance conditions. A Performance Award granted under the Plan (i) may be denominated or payable in cash, shares of Common Stock (including, without limitation, Restricted Stock), other Awards or other property, and (ii) shall confer on the holder thereof the right to receive payments, in whole or in part, upon the achievement of one or more performance goals during such performance periods as the Committee may establish within the provisions of this Article VII.

7.2    Performance Goals. The grant and/or settlement of a Performance Award shall be contingent upon terms set forth in this Section 7.2.

(a)    General. The performance goals for Performance Awards shall consist of one or more business criteria and a targeted level or levels of performance with respect to each of such criteria, as specified by the Committee. In the case of any Award granted to a Covered Employee, performance goals shall be designed to be objective and shall otherwise meet the requirements of Section 162(m) of the Code and regulations thereunder (including Treasury Regulations sec. 1.162-27 and successor regulations thereto), including the requirement that the level or levels of performance targeted by the Committee are such that the achievement of performance goals is “substantially uncertain” at the time of grant. The Committee may determine that such Performance Awards shall be granted and/or settled upon achievement of any one performance goal or that two or more of the performance goals must be achieved as a condition to the grant and/or settlement of such Performance Awards. Performance goals may differ among Performance Awards granted to any one Participant or for Performance Awards granted to different Participants. 

13

(b)    Business Criteria. One or more of the following business criteria for the Company, on a consolidated basis, and/or for specified subsidiaries, divisions or business or geographical units of the Company, shall be used by the Committee in establishing performance goals for Performance Awards granted to a Participant: (A) earnings per share; (B) increase in price per share; (C) increase in revenues; (D) increase in cash flow; (E) return on assets; (F) return on investments; (G) return on equity; (H) return on net capital employed; (I) economic value added; (J) gross margin; (K) net income; (L) earnings before interest, taxes, depreciation, depletion and amortization; (M) earnings before interest and taxes; (N) profit before taxes; (O) operating income; (P) total stockholder return; (Q) debt reduction; (R) health/safety/environmental performance; and (S) any of the above goals determined on the absolute or relative basis or as compared to the performance of a published or special index deemed applicable by the Committee including, but not limited to, the Standard & Poor’s 500 Stock Index, the Oil Service Index (OSX) or components thereof or a group of comparable companies. 

(c)    Performance Period; Timing for Establishing Performance Goals. Achievement of performance goals in respect of Performance Awards shall be measured over a performance period of not less than one year and not more than five years, as specified by the Committee, subject to the provisions of Section 8.10(d) with respect to death, Disability and Retirement and Section 8.11 with respect to a Change in Control and a termination of Employment or termination of service following a Change in Control. Performance goals in the case of any Award granted to a Participant shall be established not later than 90 days after the beginning of any performance period applicable to such Performance Awards, or at such other date as may be required or permitted for “performance-based compensation” under Section 162(m) of the Code.

(d)    Settlement of Performance Awards; Other Terms. After the end of each performance period, the Committee shall determine the amount, if any, of Performance Awards payable to each Participant based upon achievement of business criteria over a performance period. Except as may otherwise be required under Section 409A of the Code, payment described in the immediately preceding sentence shall be made by the later of (i) the date that is 2 1/2 months after the end of the Participant’s first taxable year in which the Performance Award is earned and payable under the Plan and (ii) the date that is 2 1/2 months after the end of the Company’s first taxable year in which the Performance Award is earned and payable under the Plan, and such payment shall not be subject to any election by the Participant to defer the payment to a later period. Subject to the limitation set forth in Section 1.3, with respect to any Performance Award payable in shares of Common Stock, the number of shares of Common Stock deliverable shall be determined by dividing the amount payable under a Performance Award by the FMV Per Share of Common Stock on the determination date and a stock certificate evidencing the resulting shares of Common Stock (to the nearest full share) shall be delivered to the Participant, or his personal representative, and the value of any fractional shares will be paid in cash. If at the time payment is due with respect to any Performance Award payable in shares of Common Stock there is not a sufficient number of shares of Common Stock available under the Plan to pay such Performance Award fully in shares of Common Stock, the Performance Award shall first be paid in shares of Common Stock if any, as provided above with the remaining portion of such Performance Award payable in cash. The Committee may not exercise discretion to increase any such amount payable in respect of a Performance Award which is intended to comply with Section 162(m) of the Code. The Committee shall specify the circumstances in which such Performance Awards shall be paid or forfeited by the Participant in the event of termination of a Participant’s Employment or of a Participant’s service prior to the end of a performance period or settlement of Performance Awards.

(e)    Written Determinations. All determinations by the Committee as to the establishment of performance goals, the amount of any Performance Award, and the achievement of performance goals relating to Performance Awards shall be made in a written agreement or other document covering the 

14

Performance Award. The Committee may not delegate any responsibility relating to such Performance Awards.

(f)    Status of Performance Awards Under Section 162(m) of the Code. It is the intent of the Company that Performance Awards granted to persons who are designated by the Committee as likely to be Covered Employees within the meaning of Section 162(m) of the Code and regulations thereunder (including Treasury Regulations § 1.162-27 and successor regulations thereto) shall constitute “performance-based compensation” within the meaning of Section 162(m) of the Code and regulations thereunder. Accordingly, the terms of this Section 7.2 shall be interpreted in a manner consistent with Section 162(m) of the Code and regulations thereunder. The foregoing notwithstanding, because the Committee cannot determine with certainty whether a given Participant will be a Covered Employee with respect to a fiscal year that has not yet been completed, the term Covered Employee as used herein shall mean any person designated by the Committee, at the time of grant of a Performance Award, as likely to be a Covered Employee with respect to that fiscal year. If any provision of the Plan as in effect on the date of adoption or any agreements relating to Performance Awards that are intended to comply with Section 162(m) of the Code does not comply or is inconsistent with the requirements of Section 162(m) of the Code or regulations thereunder, such provision shall be construed or deemed amended to the extent necessary to conform to such requirements. Notwithstanding any provision of this Plan to the contrary, the Committee may not increase the amount payable to a Covered Employee in respect of a Performance Award, or to otherwise amend or affect an Option, Stock Appreciation Right or Performance Award, that is intended to qualify as “performance-based compensation” under Section 162(m) of the Code to otherwise fail to qualify as “performance-based compensation” under Section 162(m) of the Code.

ARTICLE VIII
CERTAIN PROVISIONS APPLICABLE TO ALL AWARDS

8.1    General. Awards shall be evidenced by a written agreement or other document and may be granted on the terms and conditions set forth herein. In addition, the Committee may impose on any Award or the exercise thereof, such additional terms and conditions, not inconsistent with the provisions of the Plan, as the Committee shall determine, including terms requiring forfeiture of Awards by the Participant in the event of termination of a Participant’s Employment or termination of a Participant’s service and terms permitting a Participant to make elections relating to his or her Award; provided, that any such election would not (i) cause the application of Section 409A of the Code to the Award or (ii) create adverse tax consequences under Section 409A of the Code should Section 409A apply to the Award. The terms, conditions and/or restrictions contained in an Award may differ from the terms, conditions and restrictions contained in any other Award. The Committee may amend an Award; provided, however, subject to Section 8.11, no amendment of an Award may, without the consent of the holder of the Award, adversely affect such person’s rights with respect to such Award in any material respect. The Committee shall retain full power and discretion to accelerate or waive, at any time, any term or condition of an Award; provided, however, that, subject to Section 8.11, the Committee shall not have any discretion to accelerate or waive any term or condition of an Award if (x) such discretion would cause the Award to have adverse tax consequences to the Participant under Section 409A of the Code or (y) if the Award is intended to qualify as “performance-based compensation” for purposes of Section 162(m) of the Code and such discretion would cause the Award not to so qualify. Except in cases in which the Committee is authorized to require other forms of consideration under the Plan, or to the extent other forms of consideration must be paid to satisfy the requirements of the Delaware Corporation Law, no consideration other than services may be required for the grant of any Award.

    

15

8.2    Stand-Alone, Additional and Substitute Awards. 

(a)    Awards Granted by the Company and Affiliates. Subject to the limitations on repricing set forth below and in Sections 2.4 and 5.2 of the Plan, Awards granted under the Plan may, in the discretion of the Committee, be granted either alone or in addition to, or in substitution or exchange for, any other Award or any award granted under another plan of the Company or any Affiliate, or any other right of a Participant to receive payment from the Company or any Affiliate; provided, however, no Award shall be issued in tandem with another Award under the Plan or in tandem or in connection with any award granted under another plan of the Company or any Affiliate, or any other right of a Participant to receive payment from the Company or any Affiliate if such an issuance would result in adverse tax consequences under Section 409A of the Code. Such additional, substitute or exchange Awards may be granted at any time. If an Award is granted in substitution or exchange for another Award, the Committee shall require the surrender of such other Award for cancellation in consideration for the grant of the new Award. In addition, Awards may be granted in lieu of cash compensation, including in lieu of cash amounts payable under other plans of the Company or any Affiliate. Any such action contemplated under this Section 8.2(a) shall be effective only to the extent that such action will not cause (i) the holder of the Award to lose the protection of Section 16(b) of the Exchange Act and rules and regulations promulgated thereunder, (ii) any Award that is designed to qualify payments thereunder as performance-based compensation as defined in Section 162(m) of the Code to fail to qualify as such performance-based compensation, or (iii) any Award that is subject to Section 409A of the Code to result in adverse consequences under Section 409A of the Code. In addition, except in connection with a corporate transaction involving the Company (including, without limitation, any stock dividend, stock split, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, or exchange of shares), the terms of outstanding Awards may not be amended to reduce the exercise price of outstanding Options or Stock Appreciation Rights or to cancel outstanding Options or Stock Appreciation Rights in exchange for cash, other Awards or Options or Stock Appreciation Rights with an exercise price that is less than the exercise price of the original Options or Stock Appreciation Rights without prior stockholder approval.

(b)    Substitute Awards for Awards Granted by Other Entities. The Committee shall have the authority to grant substitute Awards under the Plan in assumption of, or in substitution or exchange for, any options or awards previously granted by another entity that are transferred to the Company or an Affiliate as a result of the acquisition of, or merger, consolidation or other corporate transaction with, such other entity by the Company or an Affiliate. The number of shares of Common Stock covered by any such substitute Awards shall not reduce, or otherwise be counted against, the aggregate number of shares of Common Stock available for grant under the Plan. Except as otherwise provided by applicable law and notwithstanding anything in the Plan to the contrary, the terms, provisions and benefits of the substitute Awards so granted, including, without limitation, the exercise price of any such substitute Award, may vary from those set forth in or required by the Plan to the extent the Committee at the time of grant may deem appropriate to conform, in whole or in part, to the terms, provisions and benefits of the options or awards being assumed or replaced. In addition, the date of grant of any substitute Award shall relate back to the initial option or award being assumed or replaced, and service with the acquired entity shall constitute service with the Company or its Affiliate.

    

16

8.3    Term of Awards. The term or Restricted Period of each Award that is an Option, Stock Appreciation Right or Restricted Stock shall be for such period as may be determined by the Committee; provided that in no event shall the term of any such Award exceed a period of ten (10) years (or such shorter terms as may be required in respect of an Incentive Stock Option under Section 422 of the Code). 

8.4    Form and Timing of Payment Under Awards; Deferrals. 

(a)    General Provisions. Subject to the terms of the Plan and any applicable Award agreement, payments to be made by the Company or a subsidiary upon the exercise of an Option or other Award or settlement of an Award may be made in such form or forms as the Committee shall determine, including, without limitation, cash, shares of Common Stock, other Awards or other property or any combination thereof, and may be made as a single payment or transfer, in installments, or on a deferred basis. The settlement of any Award may, subject to any limitations set forth in the Plan and/or Award agreement, be accelerated, in the discretion of the Committee or upon occurrence of one or more specified events; provided, however, that such discretion may not be exercised by the Committee if the exercise of such discretion would result in adverse tax consequences to the Participant under Section 409A of the Code. Installment or deferred payments may be required or permitted by the Committee (subject to Section 1.8 of the Plan, including the consent provisions thereof in the case of any deferral of an outstanding Award not provided for in the original Award agreement); provided, however, that no deferral shall be required or permitted by the Committee if such deferral would result in adverse tax consequences to the Participant under Section 409A of the Code. Any deferral shall only be allowed as is provided in a separate deferred compensation plan adopted by the Company. The Plan shall not constitute an “employee benefit plan” for purposes of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended.  

(b)    Section 409A Limits on Certain Payments. Notwithstanding any other provision of the Plan or an Award to the contrary, if a Participant is a “key employee,” as defined in Section 416(i) of the Code (without regard to paragraph 5 thereof), except to the extent permitted under Section 409A of the Code, no benefit or payment that is subject to Section 409A of the Code (after taking into account all applicable exceptions to Section 409A of the Code, including but not limited to the exceptions for short-term deferrals and for “separation pay only upon an involuntary separation from service”) shall be made under this Plan or the affected Award granted thereunder on account of the Participant’s “separation from service,” as defined in Section 409A of the Code, with the Company and its Affiliates until the later of the date prescribed for payment in this Plan or the affected Award granted thereunder and the first (1st) day of the seventh (7th) calendar month that begins after the date of the Participant’s separation from service (or, if earlier, the date of death of the Participant). Unless otherwise provided in the Award, any amount that is otherwise payable within the delay period described in the immediately preceding sentence will be aggregated and paid in a lump sum without interest.  Notwithstanding any other provision of the Plan or an Award to the contrary, no benefit or payment that is subject to Section 409A of the Code (after taking into account all applicable exceptions to Section 409A of the Code, including but not limited to the exceptions for short-term deferrals and for “separation pay only upon an involuntary separation from service”) shall be made under this Plan or the affected Award on account of a termination of the Participant’s Employment or service relationship with the Company and its Affiliates unless that termination also constitutes a “separation from service” as defined in Section 409A of the Code.

8.5    Vested and Unvested Awards. After the satisfaction of all of the terms and conditions set by the Committee with respect to an Award of (i) Restricted Stock, a certificate (or such other evidence of ownership), without the legend set forth in Section 6.2(c), for the number of shares that are no longer subject to such restrictions, terms and conditions shall be delivered to the Employee, and (ii) Stock Appreciation Rights or Performance Awards to be paid in shares of Common Stock, a certificate (or such other evidence of ownership) for the number of shares equal in value to the number of Stock Appreciation Rights or amount of Performance Awards payable under those Awards shall be delivered to the person. The number of shares 

17

of Common Stock which shall be issuable upon exercise of a Stock Appreciation Right or earning of a Performance Award to be paid in shares of Common Stock shall be determined by dividing (1) by (2) where (1) is the number of shares of Common Stock as to which the Stock Appreciation Right is exercised multiplied by the Spread or the amount of Performance Award that is earned and payable, as applicable, and (2) is the FMV Per Share of Common Stock on the date of exercise of the Stock Appreciation Right or the date the Performance Award is determined to be earned and payable, as applicable. Upon a termination, resignation or removal of a Participant under circumstances that do not result in such Participant to become fully vested, any remaining unvested Options, shares of Restricted Stock, Stock Appreciation Rights or Performance Awards, as the case may be, shall, unless otherwise provided in this Plan, either be forfeited back to the Company or, if appropriate under the terms of the Award, shall continue to be subject to the restrictions, terms and conditions set by the Committee with respect to such Award.

8.6    Exemptions from Section 16(b) Liability. It is the intent of the Company that the grant of any Awards to or other transaction by a Participant who is subject to Section 16 of the Exchange Act shall be exempt from Section 16(b) of the Exchange Act pursuant to an applicable exemption (except for transactions acknowledged by the Participant in writing to be non-exempt). Accordingly, if any provision of this Plan or any Award agreement does not comply with the requirements of Rule 16b-3 as then applicable to any such transaction, such provision shall be construed or deemed amended to the extent necessary to conform to the applicable requirements of Rule 16b-3 so that such Participant shall avoid liability under Section 16(b) of the Exchange Act.

8.7    Transferability.

(a)    Non-Transferable Awards and Options. Except as otherwise specifically provided in the Plan, no Award and no right under the Plan, contingent or otherwise, other than Bonus Stock or Restricted Stock as to which restrictions have lapsed, will be (i) assignable, saleable, or otherwise transferable by a Participant except by will or by the laws of descent and distribution or pursuant to a qualified domestic relations order, or (ii) subject to any encumbrance, pledge or charge of any nature. No transfer by will or by the laws of descent and distribution shall be effective to bind the Company unless the Committee shall have been furnished with a copy of the deceased Participant’s will or such other evidence as the Committee may deem necessary to establish the validity of the transfer. Any attempted transfer in violation of this Section 8.7(a) shall be void and ineffective for all purposes. 

(b)    Ability to Exercise Rights. Except as otherwise specifically provided under the Plan, only the Participant or his guardian (if the Participant becomes Disabled), or in the event of his death, his legal representative or beneficiary, may exercise Options, receive cash payments and deliveries of shares, or otherwise exercise rights under the Plan. The executor or administrator of the Participant’s estate, or the person or persons to whom the Participant’s rights under any Award will pass by will or the laws of descent and distribution, shall be deemed to be the Participant’s beneficiary or beneficiaries of the rights of the Participant hereunder and shall be entitled to exercise such rights as are provided hereunder. 

    

18

8.8    Rights as a Stockholder. 

(a)    No Stockholder Rights. Except as otherwise provided in Section 8.8(b) or Section 6.2(c), a Participant who has received a grant of an Award or a transferee of such Participant shall have no rights as a stockholder with respect to any shares of Common Stock until such person becomes the holder of record. Except as otherwise provided in Section 8.8(b) or Section 1.3, no adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities, or other property) or distributions or other rights for which the record date is prior to the date such stock certificate is issued.

(b)    Holder of Restricted Stock. Unless otherwise approved by the Committee prior to the grant of a Restricted Stock Award, a Participant who has received a grant of Restricted Stock or a permitted transferee of such Participant shall not have any rights of a stockholder until such time as a stock certificate has been issued with respect to all, or a portion of, such Restricted Stock Award, except as otherwise provided in Section 6.2(c).

8.9    Listing and Registration of Shares of Common Stock. The Company, in its discretion, may postpone the issuance and/or delivery of shares of Common Stock upon any exercise of an Award until completion of such stock exchange listing, registration, or other qualification of such shares under any state and/or federal law, rule or regulation as the Company may consider appropriate, and may require any Participant to make such representations and furnish such information as it may consider appropriate in connection with the issuance or delivery of the shares in compliance with applicable laws, rules and regulations.

8.10    Termination of Employment, Death, Disability and Retirement.

(a)    Termination of Employment or Service. Except as provided in Section 8.11 with respect to a termination of a Participant’s Employment or service following a Change in Control, if Employment of an Employee or service of a Non-Employee Director or Consultant is terminated for any reason whatsoever other than death, Disability or Retirement, then, unless otherwise provided in the Award or as otherwise determined by the Committee, any nonvested Award granted pursuant to the Plan outstanding at the time of such termination and all rights thereunder shall wholly and completely terminate and no further vesting shall occur, and the Employee, Consultant or Non-Employee Director shall be entitled to utilize his or her exercise rights with respect to the portion of the Award vested as of the date of termination for a period that shall end on the earlier of (i) the expiration date set forth in the Award with respect to the  vested portion of such Award or (ii) the date that occurs three (3) months after such termination date.

(b)    Retirement. Unless otherwise provided in the Award, upon the Retirement of a Participant:

(i)    any nonvested portion of any outstanding Award shall immediately terminate and no further vesting shall occur; and

(ii)    any exercise rights with respect to any vested Award shall expire on the earlier of (A) the expiration date set forth in the Award; or (B) the expiration of twelve (12) months after the date of Retirement.

(c)    Disability or Death. Unless otherwise provided in the Award, upon termination of a Participant’s Employment or service from the Company or any Affiliate which is a parent or subsidiary as a result of Disability or death of a Participant, or with respect to a Participant who is either a retired former Employee, Non-Employee Director or Consultant who dies during the period described in Section 8.10(b), hereinafter the “Applicable Retirement Period,” or a disabled former Employee, Non-Employee Director or Consultant who dies during the period that expires on the earlier of the expiration date set forth in any applicable 

19

outstanding Award or the first anniversary of the person’s termination of Employment or service due to Disability, hereinafter the “Applicable Disability Period,”

(i)    any nonvested portion of any outstanding Award that has not already terminated shall immediately terminate and no further vesting shall occur; and

(ii)    any exercise rights with respect to any vested Award shall expire upon the earlier of (A) the expiration date set forth in the Award or (B) the later of (1) the first anniversary of such termination of Employment or service as a result of Disability or death, or (2) the first anniversary of such person’s death during the Applicable Retirement Period (except in the case of an Incentive Option) or the Applicable Disability Period.

(d)        Acceleration of Vesting and Lapse of Restrictions. Notwithstanding the above provisions of this Section 8.10, to the extent not already provided for in the Award, upon the Retirement of a Participant, or upon termination of Employment or service as a result of the Disability or death of a Participant, the Committee, in its discretion and on an individual basis, may provide (i) with respect to any Stock Option or Stock Appreciation Right, that all or a part of the unvested portion of such Award shall become vested and, together with the previously vested portion of the Award, shall be exercisable for such period and upon such terms and conditions as may be determined by the Committee, provided that such continuation may not exceed the expiration date set forth in the Award; and, (ii) with respect to Restricted Stock, that all or a part of the unvested portion of the Award shall become vested; provided, however, that (A) if the Award is to a Covered Employee and intended to qualify as “performance-based compensation” under Section 162(m) of the Code, such acceleration of vesting and waiver of restrictions may only occur upon a termination due to death or Disability, (B) with respect to Awards that are subject to Section 409(A) of the Code, the Committee shall not have the authority to accelerate the vesting or waive any restrictions, or postpone the timing of payment or settlement of the Award in a manner that would cause such Award to become subject to the interest and penalty provisions under Section 409A of the Code, and (C) no acceleration of vesting described in this Section 8.10(d) shall be effective prior to the date of the Committee’s written determination.     

(e)    Continuation. Notwithstanding any other provision of the Plan, the Committee, in its discretion and on an individual basis, may provide with respect to any Stock Option or Stock Appreciation Right, that the vested portion of such Award shall remain exercisable for such period and upon such terms and conditions as are determined by the Committee in the event that a Participant ceases to be an Employee, Consultant or Non-Employee Director; provided, however, that such continuation may not exceed the expiration date set forth in the Award.

8.11    Change in Control

(a)    Change in Control. Unless otherwise provided in the Award or other employment, severance or change in control agreement approved by the Committee to which a Participant is a party that addresses the effect on an Award of a Change in Control or termination of a Participant’s Employment or service following a Change in Control, in which case such agreement shall control, in the event of a Change in Control, the Committee (as constituted before such Change in Control), acting in its sole discretion without the consent of any Participant, may effect one or more of the following alternatives, which may vary among individual Participants and which may vary among Awards:

(i)    the Committee may accelerate vesting and the time at which all Options and Stock Appreciation Rights then outstanding may be exercised so that those types of Awards may be exercised in full for a limited period of time on or before a specified date fixed by the Committee, after which specified date all unexercised Options and Stock Appreciation Rights and all rights of Participants thereunder shall terminate, or the Committee may accelerate vesting and the time at which Options and 

20

Stock Appreciation Rights may be exercised so that those types of Awards may be exercised in full for their then remaining term;

(ii)    the Committee may waive all restrictions and conditions of all Restricted Stock then outstanding with the result that all restrictions shall be deemed satisfied, and the Restriction Period shall be deemed to have expired, as of the date of the Change in Control or such other date as may be determined by the Committee; 

(iii)    the Committee may determine to amend Performance Awards, or substitute new Performance Awards in consideration of cancellation of outstanding Performance Awards, in order to ensure that such Awards shall become fully vested, deemed earned in full and promptly paid to the Participants as of the date of the Change in Control or such other date as may be determined by the Committee, without regard to payment schedules and notwithstanding the applicable performance cycle, retention cycle or other restrictions and conditions shall not have been completed or satisfied; and 

(iv)    the Committee may provide that any such Award be assumed by the successor or survivor entity, or a parent or subsidiary thereof, or be exchanged and substituted for similar options, restricted stock, rights or awards covering the equity of the successor or survivor, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of equity interests and prices.

The above provisions of this Section 8.11(a) do not require the Committee to take any such action and any decision made by the Committee, in its sole discretion, not to take some or all of the actions described in the preceding provisions of this Section 8.11(a) shall be final, binding and conclusive with respect to the Company and all other interested persons.    

(b)    The Committee may provide for any action described in Section 8.11(a)(i), (ii) or (iii) to occur immediately upon the Change in Control or upon the termination of Employment or service of the Participant, initiated by the successor or survivor entity under such circumstances as may be specified by the Committee, within a fixed time following the Change in Control.  Any such action taken by the Committee may vary among individual Participants and among Awards.

(c)    Right of Cash-Out. If approved by the Board prior to any Change in Control described in clauses (ii), (iii) or (iv) of the definition of a Change in Control, or prior to or within thirty (30) days after any Change in Control described in clause (i) of the definition of a Change in Control shall be deemed to have occurred, the Board shall have the right upon such Change in Control or for a forty-five (45) day period immediately following the date that the Change in Control is deemed to have occurred to require all, but not less than all, Participants to transfer and deliver to the Company all Awards previously granted to the Participants in exchange for an amount equal to the “cash value” (defined below) of the Awards. Such right shall be exercised by written notice to all Participants. For purposes of this Section 8.11(c), the cash value of an Award shall equal the sum of (i) the cash value of all benefits to which the Participant would be entitled upon settlement or exercise of any Award which is not an Option or Restricted Stock and (ii) in the case of any Award that is an Option or Restricted Stock, the excess of the “market value” (defined below) per share over the option price, or the market value (defined below) per share of Restricted Stock, multiplied by the number of shares subject to such Award. In the case of any Option or Stock Appreciation Right with an exercise price (or deemed exercise price in the case of a Stock Appreciation Right) that equals or exceeds the price paid for a share of Common Stock in connection with the Change in Control, the Committee may cancel such Option or Stock Appreciate Right without the payment of consideration therefor.  For purposes of the preceding sentence, “market value” per share shall mean the higher of (i) the average of the Fair Market Value Per Share of Common Stock on each of the five trading days immediately following the date a Change in Control is deemed to have occurred or (ii) the highest price, if any, offered in connection with 

21

the Change in Control. The amount payable to each Participant by the Company pursuant to this Section 8.11(c) shall be in cash or by certified check and shall be reduced by any taxes required to be withheld.  

8.12    Clawback/Recoupment Policy. Notwithstanding any provisions in the Plan or any Award agreement to the contrary, any Award granted and/or amount payable or paid hereunder, whether in the form of cash or otherwise, shall be subject to potential cancellation, rescission, clawback and recoupment (i) to the extent necessary to comply with the requirements of Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and any regulations or listing requirements promulgated thereunder, and/or (ii) as may be required in accordance with the terms of any clawback/recoupment policy as may be adopted by the Company to comply with Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and any regulations or listing requirements promulgated thereunder, as such policy may be amended from time to time (the “Policy”). Any adoption of the Policy or amendment thereof shall not require the prior consent of any Participant.

ARTICLE IX
WITHHOLDING FOR TAXES

Any issuance or delivery of Common Stock pursuant to the exercise of an Option or in payment of any other Award under the Plan shall not be made until appropriate arrangements satisfactory to the Company have been made for the payment of any tax amounts (federal, state, local or other) that may be required to be withheld or paid by the Company with respect thereto at the minimum statutory rate. Such arrangements may, at the discretion of the Committee, include allowing the person to tender to the Company shares of Common Stock owned by the person for a period of at least twelve months prior to the date of exercise, vesting, lapse of restriction or payment of the Award, or to request the Company to withhold shares of Common Stock otherwise issuable or deliverable to the Participant pursuant to the Award, in each case which have an aggregate FMV Per Share as of the date of such withholding that is not greater than the sum of all tax amounts to be withheld with respect thereto at the minimum statutory rate, together with payment of any remaining portion of such tax amounts in cash or by check payable and acceptable to the Company. 

ARTICLE X
MISCELLANEOUS

10.1    No Rights to Awards or Uniformity Among Awards. No Participant or other person shall have any claim to be granted any Award, there is no obligation for uniformity of treatment of Participants, or holders or beneficiaries of Awards and the terms and conditions of Awards need not be the same with respect to each recipient. 

10.2    Conflicts with Plan. In the event of any inconsistency or conflict between the terms of the Plan and an Award, the terms of the Plan shall govern.

10.3    No Right to Employment. The grant of an Award shall not be construed as giving a Participant the right to be retained in the employ of the Company or any Affiliate. Further, the Company or any Affiliate may at any time dismiss a Participant from employment, free from any liability or any claim under the Plan, unless otherwise expressly provided in the Plan or in any Award.

    

22

10.4    Governing Law. The validity, construction, and effect of the Plan and any rules and regulations relating to the Plan shall be determined in accordance with applicable federal law and the laws of the State of Delaware, without regard to any principles of conflicts of law.

10.5    Gender, Tense and Headings. Whenever the context requires such, words of the masculine gender used herein shall include the feminine and neuter, and words used in the singular shall include the plural. Section headings as used herein are inserted solely for convenience and reference and constitute no part of the Plan.

10.6    Severability. If any provision of the Plan or any Award is or becomes or is deemed to be invalid, illegal, or unenforceable in any jurisdiction or as to any Participant or Award, or would disqualify the Plan or any Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to the applicable laws, or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan or the Award, such provision shall be stricken as to such jurisdiction, Participant or Award and the remainder of the Plan and any such Award shall remain in full force and effect.

10.7    Stockholder Agreements. The Committee may condition the grant, exercise or payment of any Award upon such person entering into a stockholders’ or repurchase agreement in such form as approved from time to time by the Board.

10.8    Funding. Except as provided under Article VI of the Plan, no provision of the Plan shall require or permit the Company, for the purpose of satisfying any obligations under the Plan, to purchase assets or place any assets in a trust or other entity to which contributions are made or otherwise to segregate any assets, nor shall the Company maintain separate bank accounts, books, records or other evidence of the existence of a segregated or separately maintained or administered fund for such purposes. Participants shall have no rights under the Plan other than as unsecured general creditors of the Company except that insofar as they may have become entitled to payment of additional compensation by performance of services, they shall have the same rights as other Employees, Consultants or Non-Employee Directors under general law.

10.9    No Guarantee of Tax Consequences. None of the Board, the Company nor the Committee makes any commitment or guarantee that any federal, state or local tax treatment will apply or be available to any person participating or eligible to participate hereunder.

23chrs-ex101_337.htm

 

Exhibit 10.1

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

TASK ORDER

MEDPACE Task Order Number: 23

MEDPACE Project Number: ETA305

This Task Order, dated November 12, 2014 , is between Medpace, Inc. (“Medpace”), and Coherus BioSciences, Inc.  (“Sponsor”).

RECITALS:

WHEREAS, Medpace and Sponsor have entered into that certain Master Services Agreement dated January 23, 2012 (the “Master Services Agreement”); and

WHEREAS, pursuant to the Master Services Agreement, Medpace has agreed to perform certain Services in accordance with Task Orders from time to time entered into by the Parties and Sponsor and Medpace now desire to enter into such a Task Order; 

WHEREAS, Medpace and Sponsor entered into a Limited Scope Agreement dated 9 February 2015 (“Limited Scope Agreement”), which amended and replaced the original Limited Scope Agreement dated 12 November 2014 wherein Medpace provided a limited set of activities related to the start up with respect to a Phase 3, An Open-label, Safety Extension Study evaluating the Long-term Safety and Response of CHS-0214   (CHS-0214-05) (the “Study”) for the study of the product CHS-0214 (“Study Product”); and

WHEREAS, now Medpace and Sponsor desire to enter into a Task Order whereby Medpace provide certain services as described herein with respect to the Study; 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties hereby agree as follows:

	
1.
	
Scope of Work:  Medpace shall perform the services set forth in the Scope of Work, attached hereto as Appendix A, in accordance with the Timeline, attached hereto as Appendix B and any other documents attached to and specifically referenced in this Task Order (“Services”). 

	
2.
	
Compensation:  For performance of these Services, Sponsor shall pay to Medpace an amount equal to the Services and Budget set forth in Appendix C, attached hereto and incorporated herein, which amount shall be payable pursuant to the Payment Schedule set forth in Appendix D, attached hereto and incorporated herein.  It is agreed that [***].  Any [***] shall be [***] attached hereto as Appendix G and incorporated herein. The assumptions underlying the Services and Budget are set forth in Appendix A which is attached hereto and incorporated herein.  After staff is assigned, costs are incurred based upon allocation of staff capacity.  Any invoices under this Task Order may be sent to the appropriate Sponsor contact at [***].

	
3.
	
Transfer of Obligations:  Sponsor Obligations transferred to Medpace by Sponsor (consistent with the regulations set forth in 21 C.F.R. Section 312, Subpart D) are identified in Appendix E.  

	
4.
	
MSA. The provisions of the Master Services Agreement are hereby expressly incorporated by reference into and made a part of this Task Order.

 

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 1 of 44

 

	
5.
	
[***].  All Medpace Services will be charged using the [***] set forth in Appendix I attached hereto.

	
6.
	
The MRL Services and Budget included in the Medpace Services and Budget is set forth in Appendix F attached hereto and incorporated herein. 

	
7.
	
The [***] included in the Medpace Services and Budget is set forth in Appendix G attached hereto and incorporated herein.

	
8.
	
The Investigator Payment Detail included in the Medpace Services and Budget is set forth in Appendix H attached hereto and incorporated herein.

	
9.
	
Limited Scope Agreement.  The parties agree that the Limited Scope Agreement is superseded by this Task Order.

IN WITNESS WHEREOF, the Parties have hereunto signed this Task Order effective as of the day and year first written above.

 

	
MEDPACE, INC.
	
 

	
 
	
 
	
 
	
 

	
Signature:
	
 
	
/s/ John Wynne
	
 

	
 
	
 
	
 
	
 

	
By:
	
 
	
John Wynne
	
 

	
 
	
 
	
(Print Name)
	
 

	
Title: 
	
 
	
Vice President 
	
 

	
 
	
 
	
Commercial Operations
	
 

	
Date: 
	
 
	
June 9, 2015
	
 

 

	
COHERUS BIOSCIENCES, INC.
	
 

	
 
	
 
	
 
	
 

	
Signature:
	
 
	
/s/ Dennis Lanfear
	
 

	
 
	
 
	
 
	
 

	
By:
	
 
	
Dennis Lanfear
	
 

	
 
	
 
	
(Print Name)
	
 

	
Title: 
	
 
	
CEO
	
 

	
 
	
 
	
 
	
 

	
Date: 
	
 
	
5 June, 2015
	
 

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 2 of 44

 

List of Appendices:

 

Appendix A: Scope of Work

Appendix B:  Timeline

Appendix C:  Services and Budget

Appendix D:  Payment Schedule

Appendix E:  Transfer of Obligations

Appendix F:  MRL Services and Budget

Appendix G:  [***]

Appendix H:  Investigator Payment Estimate Detail  

Appendix I:  [***]  

 

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 3 of 44

 

Appendix A:  scope of work

 

	
ITEM 
	
DESCRIPTION
	
 

	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
[***]
	
 
	
 

	
 
	
[***]
	
 
	
[***]
	
[***]
	
 
	
 

	
 
	
[***]
	
 
	
[***]
	
[***]
	
 
	
 

	
 
	
[***]
	
 
	
 
	
[***]
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
[***]
	
[***]
	
 

	
 
	
[***]
	
 
	
 
	
[***]
	
[***]
	
 

	
 
	
[***]
	
 
	
 
	
[***]
	
[***])
	
 

	
 
	
[***]
	
 
	
[***]
	
[***]
	
 
	
 

	
 
	
[***]
	
 
	
 
	
[***]
	
[***]
	
 

	
 
	
[***]
	
[***]
	
[***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
 
	
 
	
 
	
 
	
 

	
 
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 4 of 44

 

Project Start-Up

 

	
[***]
	
[***]
	
[***]
	
ITEM
	
DESCRIPTION

	
[***]
	
 
	
 
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
 

	
[***]
	
 
	
 
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
[***]
	
 
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]

	
[***]
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 5 of 44

 

Clinical Operations

 

	
[***]
	
[***]
	
[***]
	
ITEM
	
DESCRIPTION

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
[***]
	
 
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
[***]
	
 
	
 
	
[***]
	
 

	
[***]
	
 
	
 
	
[***]
	
 

	
[***]
	
 
	
 
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
[***]
	
 
	
 
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
 

Clinical Monitoring

 

	
[***]
	
[***]
	
[***]
	
ITEM
	
DESCRIPTION

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 6 of 44

 

Clinical Safety

 

	
[***]
	
[***]
	
[***]
	
ITEM
	
DESCRIPTION

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

Randomization and Supply Management 

 

	
[***]
	
[***]
	
[***]
	
ITEM
	
DESCRIPTION

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 7 of 44

 

Data Management

 

	
[***]
	
[***]
	
[***]
	
ITEM
	
DESCRIPTION

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
 
	
[***]
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
 
	
[***]
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

Statistical Analysis

 

	
[***]
	
[***]
	
[***]
	
ITEM
	
DESCRIPTION

	
[***]
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 8 of 44

 

Data Safety Monitoring Board

 

	
[***]
	
[***]
	
[***]
	
ITEM
	
DESCRIPTION

	
 
	
 
	
[***]
	
[***]
	
[***]

	
 
	
 
	
[***]
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

Medical Writing

 

	
[***]
	
[***]
	
[***]
	
ITEM
	
DESCRIPTION

	
 
	
[***]
	
 
	
[***]
	
[***]

	
[***]
	
 
	
 
	
[***]
	
 

	
 
	
[***]
	
 
	
[***]
	
[***]

	
[***]
	
 
	
 
	
[***]
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

	
 
	
[***]
	
 
	
[***]
	
[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 9 of 44

 

APPENDIX B:  TIMELINE

 

	
TASK
	
DATE

	
[***] 
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 10 of 44

 

APPENDIX C:  SERVICES AND BUDGET

 

	
Medpace Service Category
	
Fee

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 11 of 44

 

	
Medpace Service Category
	
Fee

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
Total Service Fees
	
[***]

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 12 of 44

 

 

	
Prefunded & Pass-Through Expenses 
	
Fee

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
Total Prefunded & Pass-Through Expenses
	
[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 13 of 44

 

APPENDIX D:  PAYMENT SCHEDULE 

[***]

[***] of this Task Order [***] of the total Pre-funded Expenses are due.  [***]. Sponsor shall pay such invoice [***].  [***] received from Sponsor, [***].  Medpace shall apply the [***] Pre-funded amount paid [***] against the [***], and [***].

Pass-through Costs will be billed to Sponsor [***].  Sponsor shall pay such invoice within [***] of receipt.

Pass-through Costs and Pre-funded Expenses

Any sums quoted with respect to Pass-through Costs and Pre-funded Expenses [***].  While Medpace will [***].  Payments made to third parties are [***]. 

Pass-through Costs may include, but are not limited to, [***].  Costs associated with, [***] are as detailed in the table below.

 

	
Item
	
Cost*
	
Description

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
[***] 
	
[***]
	
 

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
[***] 
	
[***]
	
[***]

	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]

	
*
	
Currency is [***]. Costs are subject to change based on [***].  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 14 of 44

 

Medpace will pass-through [***].  This will include [***].

 

	
Item
	
Cost
	
Description

	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
 

 

	
*
	
Currency is [***]

Pre-funded Expenses

Pre-funded Expenses may include, but are not limited to, [***].  Investigator fees are [***].  The investigator fee amount [***].  The laboratory fee amount [***]. With the exception of [***], Medpace will seek the prior written approval of the budget by Sponsor before signing an agreement (including amendments) with Pre-funded Vendors. 

Additional Costs

[***]

All Direct Fees are [***].  All such changes [***]

[***].  After staff are assigned, [***].

Inflation

[***]

Currency and Exchange Rate

The currency of this Task Order is United States Dollars unless otherwise provided herein. 

Medpace will invoice Sponsor for Pass-through Costs and Pre-funded Expenses incurred and/or [***].  The Direct Fees detailed in this Task Order were calculated using [***].  [***].  

[***]

Applicable Taxes

All Direct Fees, Pass-through Costs, and Pre-funded Expenses are quoted excluding any [***], which include but are not limited to [***], which may be payable to Medpace by Sponsor.

 

 

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 15 of 44

 

APPENDIX E:  TRANSFER OF OBLIGATIONS

CONFIDENTIAL

Directions:  Complete the form below for Sponsor obligations that have been transferred in accordance with 21 CFR Part 312, Subpart D (Responsibilities of Sponsors).  Forward the completed form to Sponsor’s Regulatory Affairs Department for submission to the applicable regulatory agencies.

 

				
	
Drug:
	
CHS-0214 
	
Study ID:
	
 CHS-0214-05

	
Study Title:
	
An Open-label, Safety Extension Study evaluating the Long-term Safety and Response of CHS-0214   (CHS-0214-05)

	
CRO Name:
	
Medpace

	
CRO Address:
	
5375 Medpace Way, Cincinnati, Ohio  45227

 

		
	
Obligations Transferred to Medpace: R the Appropriate Box(es).

o All obligations in 21 CFR 312, Subpart D (Responsibilities of Sponsors) have been transferred to Medpace.

x The following obligations have been transferred to Medpace:

	
Sec. 312.32:  IND Safety Reports

x  Promptly review safety information.

x  Notify all participating investigators in a written IND safety report of any AE associated with the drug that is both serious and unexpected. 

o  Notify the FDA in a written IND safety report of any AE associated with the drug that is both serious and unexpected.

 

Sec. 312.53:  Selecting investigators and monitors

x  (a) Select qualified investigators

x  (b) Control investigational drug shipment in collaboration with sponsor and drug vendor

x  (c) Obtain information from investigators

x  (1) Signed Form FDA-1572

x  (2) CV or other qualification statement

x  (3) Clinical protocol outline

x  (4) Financial disclosure information

x  (d) Select qualified monitors

 

Sec. 312.54:  Emergency research

o  (a) Monitor the progress of all studies involving an exception from informed consent.

x  (b) Monitor such studies to identify when an IRB determines that it can’t approve the research in collaboration with sponsor.

 

Sec. 312.55:  Informing investigators

x  (a) Provide sites with the current Inv. Brochure.

x  (b) Inform investigators of new observations on the drug, particularly with respect to AEs and safe use.

 

Sec. 312.56:  Review of ongoing investigations

o  (a) Monitor the progress of all IND studies.

x  (b) Secure compliance from noncompliant investigators or discontinue drug shipments and end the investigator’s participation in the study in collaboration with sponsor and drug vendor.

x  (c) Review and evaluate the safety and efficacy results as it is obtained from the investigator.

x  (d) Discontinue use of the investigational drug if it is determined to present an unreasonable and significant risk to subjects, notify all IRBs and investigators, and assure the return or alternate disposition of the drug from the investigators in collaboration with sponsor and drug vendor.
	
Sec. 312.57:  Record keeping and record retention

x  (a) Maintain adequate records showing investigational drug receipt, shipment, or other disposition in collaboration with sponsor and drug vendor.

x  (b) Maintain complete and accurate records showing any financial interests of the investigator subject to 21 CFR 54.

o  (c) Retain the records and reports required by the regulations for 2 years after the marketing application is approved, or if not approved, until 2 years after investigational drug shipment is discontinued and FDA has been notified.

o  (d) Retain reserve samples of any test article and reference standard identified and used in bioequivalence or bioavailability studies.

 

Sec. 312.58:  Inspection of Sponsor’s records and reports

x  (a) Permit FDA personnel to have access to and copy and verify any records and reports related to the clinical investigation.

x  (b) Permit DEA personnel to have access to and copy records related to the shipment, delivery, receipt and disposition of any investigational controlled substance.  Assure adequate storage precautions are taken for investigational new drug substances listed in any schedule of the Controlled Substances Act.

 

Sec. 312.59:  Disposition of unused supply of investigational drug

x  Assure the return (or alternate disposition) of all unused supplies of the investigational drug from each discontinued/terminated investigator; maintain written records of any disposition of the investigational drug in collaboration with sponsor and drug vendor.

 

Other

 

o  Please describe any other applicable transfers below: 

 

 

 

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 16 of 44

 

APPENDIX F:  MRL Services and Budget

See attached budget on next page.

 

 

 

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 17 of 44

 

 

			
	
Sponsor:
	
Coherus BioSciences
	
[***]

	
Protocol:
	
CHS-0214-05
	
 

 

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

 

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

	
 
	
 

	
Total Medpace Reference Laboratories Fees
	
[***]

 

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 18 of 44

 

 

	
Medpace Reference Laboratories Fee Estimate

[***]

	
Sponsor       Coherus BioSciences
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Protocol:    CHS-0214-05
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
[***]
	
 
	
 
	
 

	
 
	
Unit Cost
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
Total Number of Units
	
Cost
	
Subtotal

	
Laboratory Tests
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
[***]
	
 
	
 
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Laboratory Support Services
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Total Medpace Reference Laboratory Fees
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 19 of 44

 

	
Medpace Reference Laboratories Fee Estimate

[***]

	
Sponsor       Coherus BioSciences
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Protocol:     CHS-0214-05
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
[***]
	
 
	
 
	
 

	
 
	
Unit Cost
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
Total Number of Units
	
Cost
	
Subtotal

	
Laboratory Tests
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Laboratory Support Services
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Total Medpace Reference Laboratory Fees
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 20 of 44

 

	
Medpace Reference Laboratories Fee Estimate

[***]

	
Sponsor       Coherus BioSciences
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Protocol:     CHS-0214-05
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
[***]
	
 
	
 
	
 

	
 
	
Unit Cost
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
Total Number of Units
	
Cost
	
Subtotal

	
Laboratory Tests
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Laboratory Support Services]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Total Medpace Reference Laboratory Fees
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
[***]

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 21 of 44

 

	
Medpace Reference Laboratories Pass Through Fee Estimate

 

	
Sponsor       Coherus BioSciences

	
Protocol:     CHS-0214-05

	
 
	
Average Cost 
per Unit
	
Estimated 
Number of 
Units
	
Total Cost
	
Subtotal

	
Pass Through Estimates
	
 
	
 
	
 
	
[***]

	
[***]
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
Total Medpace Reference Laboratory Fees
	
 
	
 
	
 
	
[***]

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 22 of 44

 

Transportation Rates

 

													
	
Country
	
Sites
	
Number Randomized
	
Number Ambient / Refrigerate Shipments
	
Number Frozen Shipments
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
 
	
[***]
	
 
	
[***]

	
 
	
 
	
[***]
	
 
	
 
	
[***]
	
[***]
	
 
	
 

	
 
	
 
	
[***]
	
 
	
 
	
[***]
	
[***]
	
 
	
 

	
 
	
 
	
[***]
	
 
	
 
	
[***]
	
[***]
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
 
	
[***]
	
 
	
[***]

 

[***]

[***]

		

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 23 of 44

 

	
Transportation Rates
	
[***]

 

	
Country
	
Sites
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
 
	
[***]
	
 
	
[***]
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
 
	
[***]
	
 
	
[***]
	
[***]

 

 

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 24 of 44

 

APPENDIX G:  [***]

See attached budget on next page.

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 25 of 44

 

TASK ORDER #6

SUBCONTRACTOR Task Order Number: 6 

SUBCONTRACTOR Project Number: CHS-0214-05

This Task Order, dated October 27th, 2014, is between Medpace, Inc. (“PRIME“), and [***] (“Subcontractor“).

RECITALS:

WHEREAS, PRIME and Subcontractor have entered into that certain Master Subcontract Agreement dated 1 October 2012 (the “Master Subcontract Agreement”); and

WHEREAS, pursuant to the Master Subcontract Agreement, Subcontractor has agreed to perform certain Services in accordance with Task Orders from time to time entered into by the Parties and PRIME and Subcontractor now desire to enter into such a Task Order; and

WHEREAS, Subcontractor may subcontract the portion of clinical study activities to [***], an affiliate of Subcontractor (“[***]”); and

WHEREAS, Subcontractor and PRIME desire that Subcontractor provide certain services with respect to a Double-Blind, Randomized, Parallel-Group, Active-Control Study to compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects with Rheumatoid Arthritis and Inadequate Response to Treatment with Methotrexate (the “Study”) for the study of the product CHS-0214 (“Study Product”) as set out in the Protocol Number: CHS-0214-05, which is incorporated herein by reference, sponsored by Coherus Biosciences, Inc. (the “Sponsor”);

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties hereby agree as follows:

	
1.
	
Scope of Work. PRIME agrees that [***] shall perform the services described in the Scope of Work, attached hereto as Appendix 1, in accordance with the Project Schedule, attached hereto as Appendix 2 and any other documents attached to and specifically referenced in this Task Order (“Services”). PRIME acknowledges [***] will perform the Services on behalf of Subcontractor. PRIME may communicate with [***] directly and accepts [***]'s direct communication to PRIME relating to the Services.

	
2.
	
Performance Standards. [***] performs the Services pursuant to Master Subcontract Agreement and this Task Order in compliance with the Applicable Law, GCP, PRIME's standard operating procedures (“SOP”) and other protocol provided prospectively to Subcontractor for review. The Parties including [***] may amend the SOP if [***].

	
3.
	
Provision of Documents.  For the performance of the Services, PRIME shall provide [***] with documents, information, data and so forth (including duplicates and copies, hereinafter referred to as the “Service Documents”). If it materially delays or suspends performance of the Services, and such delay is not attributable only to Subcontractor and/or [***], then the parties including [***] shall discuss and negotiate in good faith on revised timeline and re-staffing or re-allocation of resources.

	
4.
	
Respect for Human Rights of Subject. The Parties shall give the priority to the respect of human rights of the subjects, and shall protect the privacy of the subjects in the course of the execution of clinical trial and process of the Monitoring-related Services, and ensure patient safety.

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 26 of 44

 

	
5.
	
Confirmation and Instruction. PRIME has the right to give [***] instructions regarding performance of the Services. The instructions shall be made in writing, as a general rule. In the event any instruction is given in a form other than writing out of necessity, a document specifying such instruction shall be delivered to [***] thereafter as soon as possible.

	
6.
	
Reporting. [***] shall provide a written report about actions taken based on the preceding sections without delay to PRIME.

	
7.
	
Compensation. For performance of these Services, PRIME shall pay to [***], upon [***]'s invoice, an amount equal to the Project Costs set forth in Appendix 3, which amount shall be payable pursuant to the Payment Schedule set forth in Appendix 4.  [***].

	
8.
	
Term and Termination. The term of this Task Order shall commence upon execution of this Task Order by Subcontractor and PRIME shall continue until completion of Services as described in Appendix 1, provided, however, either Party may terminate this Task Order in accordance with the Master Subcontract Agreement.

	
9.
	
Archival Documents of the Services. Subcontractor shall make [***] store the following materials (the “Records”) which may certify the reliability and quality of the Monitoring-related Services, [***], for [***] after the termination of the Services, in accordance with the SOP. The manner of storing the Records and the treatment thereof after the expiration of the storing term and the expenses shall be determined through a separate and mutual consultation between the Parties including [***].

	
(1)
	
Essential Documents which are defined in GCP

	
(2)
	
Any other materials which Subcontractor is obligated to store by the SOP. 

	
10.
	
Survival. Notwithstanding the terms of Master Subcontract Agreement, upon termination or expiration of this Task Order, the obligations of the Parties will cease other than the obligations under the following provisions, which will remain in full force and effect to the extent provided below:

Article 8 (CONFIDENTIALITY) of the Master Subcontract Agreement will survive for [***] after the termination of this Task Order.

	
11.
	
Sponsor. The Parties hereto acknowledge and agree that the Sponsor is a third-party beneficiary under this Task Order, entitled to enforce directly and all of its rights and PRIME'S rights hereunder.

	
12.
	
MSA. The provisions of the Master Subcontract Agreement are hereby expressly incorporated by reference into and made a part of this Task Order.

	
13.
	
Project Schedule. The Project Schedule for this Task Order is attached as Appendix 2.

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 27 of 44

 

	
14.
	
Limitation of Liability. IN ADDITON TO THE TERMS OF ARTICLE 15 OF MASTER SUBCONTRACT AGREEMENT, THE PARTIES AGREE TO THE TOTAL LIABILITY OF SUBCONTRACTOR UNDER OR IN CONNECTION WITH THIS TASK ORDER SHALL BE LIMITED TO THE SUM OF THE PAYMENTS FOR SUBCONTRACTOR AND THE SERVICES SET FORTH IN THIS TASK ORDER ON APPENDIX 3 RECEIVED BY [***] FROM PRIME UNDER THIS TASK ORDER EXCEPT IN CASE OF (1) WILLFUL MISCONDUCT, GROSS NEGLIGENCE OF SUBCONTRACTOR OR [***], OR (ii) AN ACTION OR INACTION THAT IS NOT IN COMPLIANCE WITH THIS TASK ORDER OR THE PROTOCOL, OR BREACH OF ANY APPLICABLE FEDERAL, STATE, OR LOCAL LAW TO THE EXTENT THAT CAUSE MATERIAL LOSS TO PRIME.

	
15.
	
Conflict. In the event of any conflict between the terms of the Master Subcontract Agreement or this Task Order, this Task Order shall govern.

	
16.
	
Governing Law. This Task Order shall be governed in accordance with the laws of Japan.

	
17.
	
Effectiveness. All other terms and conditions of the Master Subcontract Agreement and this Task Order remain in full force and effect. All capitalized terms not defined in this Task Order have the meanings given to them in the Master Subcontract Agreement. 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 28 of 44

 

IN WITNESS WHEREOF, the Parties have hereunto signed this Task Order effective as of the day and year first written above.

MEDPACE, INC.

 

	
Signature:  
	
/s/ John Wynne
	
 

	
 
	
 
	
 

	
By: 
	
John Wynne
	
 

	
 
	
 
	
 

	
Title: 
	
Vice President Commercial Operations
	
 

[***]

 

	
Signature: [***]  
	
 
	
 

	
 
	
 

	
By: [***]
	
 

	
 
	
 

	
Title: Chairman and CEO
	
 

List of Appendices:

Appendix 1: Scope of Work 

Appendix 2: Project Schedule 

Appendix 3: Project Budget 

Appendix 4: Payment Schedule

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 29 of 44

 

Appendix 1: Scope of Work

		
	
Item
	
Description

	
[***]
	
[***]

	
[***]
	
[***]

	
[***]
	
[***]

 

					
	
[***]
	
[***]
	
[***]
	
ITEM
	
DESCRIPTION

	
 
	
 
	
[***]
	
[***]
	
[***]

	
[***]
	
 
	
 
	
[***]
	
[***]

	
 
	
 
	
[***]
	
[***]
	
[***]

 

Appendix 2: Project Schedule

 

		
	
MILESTONE
	
APPROXIMATE DATE

	
[***]
	
[***]

 

 

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 30 of 44

 

Appendix 3: Project Budget

 

	
 
	
Estimation Date: [***]
Estimate #: [***]

	
1. [***]
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
Detailed cost estimate
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
CHS-0214-05 study [***]

	
 
	
Total:
	
[***]

	
 
	
 
	
 
	
 

	
Summary
	
Unit price [***]
	
[***]
	
Cost [***]

	
I. [***]
	
 
	
 
	
[***]

	
 
	
 
	
 
	
 

	
1. [***]

	
(1) [***]
	
[***]
	
[***]
	
[***]

	
(2) [***]
	
[***]
	
[***]
	
[***]

	
(3) [***]
	
[***]
	
[***]
	
[***]

	
(4) [***]
	
[***]
	
[***]
	
[***]

	
 
	
 
	
 
	
 

	
2  [***]

	
(1) [***]
	
[***]
	
[***]
	
[***]

	
(2) [***]
	
[***]
	
[***]
	
[***]

	
(3) [***]
	
[***]
	
[***]
	
[***]

	
(4) [***]
	
[***]
	
[***]
	
[***]

	
 
	
 
	
 
	
 

	
3  [***]
	
[***]
	
[***]
	
 

	
 
	
 
	
 
	
 

	
II.  [***]
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
1.      [***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
2.      [***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
3.      [***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
4.      [***]
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
III.  [***]
	
[***]
	
[***]
	
[***]

	
Total [***]
	
 
	
 
	
[***]

	
 
	
 
	
 
	
 

	
Note:
	
 
	
 
	
 

	
 - [***]

	
 - [***]

	
 - [***]

	
 
	
 
	
 
	
 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 31 of 44

 

Appendix 4: Payment Schedule

Subcontractor will submit, in accordance with the Project Budget, itemized invoice on [***]. Such invoice will be [***]. Such invoice itemization shall [***] to allow for [***].

Pass-Through expenses will be paid by [***] on [***].

In no event shall total costs for Services rendered by Subcontractor under this Task Order exceed the amount of [***] without [***].

PRIME shall make payments to Subcontractor by wire transfer to its designated bank account within [***] after [***] as applicable.

Subcontractor shall send all invoices to the following PRIME accounting contact to the email address by PDF:

The invoice should indicate the following information.

Medpace, Inc.

5375 Medpace Way 

Cincinnati, Ohio 45227

Tel:     +1.513.579.9911

Fax:    +1.513.579.0444

E-mail: [***] 

Invoices must be received within [***] of the [***] included in the invoice. Invoices received [***] will [***].

Within [***] of completion of the Services, Subcontractor shall submit a final invoice to PRIME according to the terms in this Agreement and the particular Task Order.

Other as set for the in this Task Order, payment terms shall be as defined in Section 4 of the Master Subcontract Agreement.

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 32 of 44

 

CONFIDENTIAL

 

		
	
Medpace, Inc.
	
Estimation Date: [***]

	
 
	
Estimate #[***]

 

		
	
Cost Estimate
	
 

	
CHS-0214-05 study [***]
	
[***]

	
[***]
	
 

 

	
ITEMS
	
Current [***]
	
Current [***]
	
Previous [***]
	
Previous [***]
	
Balance [***]
	
Balance [***]

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
1. [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
2. [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Total
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
 

	
[***]
	
Current [***]
	
Current [***]
	
Previous [***]
	
Previous [***]
	
Balance [***]
	
Balance [***]

	
1) [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
2) [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
3) [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Total
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
Grand Total
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

 

Note

 

- [***]: [***]

- [***]: [***]

- [***]

 

- [***]

 

- [***]

- [***]

 

- [***]

 

- [***]

 

[***]

[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 33 of 44

 

CONFIDENTIAL

 

Estimation Date: [***] 
Estimate #[***]

 

1. [***] 

 

Detailed cost estimate

 

CHS-0214-05 study [***]

[***]

 

		
	
Total:
	
[***]

 

	
Summary                 [***]                  [***]                [***]             [***]
	
[***]
	
[***]
	
Balance

	
I             Site payment management
	
[***]
	
[***]
	
[***]

	
[***]            [***] presumably             [***]            [***]            [***]           sites
	
[***]
	
[***]
	
[***]

	
[***]
	
 
	
 
	
 

	
* [***]
	
 
	
 
	
 

	
* [***]
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
II          [***]
	
[***]
	
[***]
	
[***]

	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 

	
●[***]
	
 
	
 
	
 

	
●[***]
	
 
	
 
	
 

	
  [***]
	
 
	
 
	
 

	
●[***]
	
 
	
 
	
 

	
  [***]
	
 
	
 
	
 

	
●[***]
	
 
	
 
	
 

	
   [***]
	
 
	
 
	
 

	
●[***]
	
 
	
 
	
 

	
●[***]
	
 
	
 
	
 

	
III           [***]
	
[***]
	
[***]
	
[***]

	
III           [***]
	
[***]
	
[***]
	
[***]

	
Total [***]
	
[***]
	
[***]
	
[***]

	
 

	
V           [***]
	
 
	
 
	
 

	
 
	
 
	
 
	
 

	
1 [***]
	
 
	
 
	
 

	
2 [***]
	
 
	
 
	
 

	
3 [***]
	
 
	
 
	
 

	
4 [***]
	
 
	
 
	
 

	
5 [***]
	
 
	
 
	
 

	
 
	
 
	
 
	
 

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 34 of 44

 

CONFIDENTIAL

 

Estimation Date: [***]

Estimate #[***]

 

2. [***]

 

Detailed cost estimate

							
	
―Assumptions―
	
 
	
 
	
 
	
 

	
1) [***]:
	
[***]
	
12) [***]: [***]

	
2) [***]:
	
[***]
	
 
	
 
	
 

	
3) [***]:
	
[***]
	
1[***]:
	
[***]

	
4) [***]:
	
[***]
	
2[***]:
	
[***]

	
5) [***]:
	
[***]
	
3[***]:
	
[***]

	
6) [***]:
	
[***]
	
4[***]:
	
[***]

	
7) [***]:
	
[***]
	
5[***]:
	
[***]

	
8) [***]
	
[***]
	
6[***]
	
[***]

	
9) [***]
	
[***]
	
 
	
 
	
 

	
10)[***]:
	
[***]
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
[***]:
	
 
	
[***]

 

		
	
Total:
	
[***]

 

							
	
Summary
	
Unit price [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
Balance
[***]

	
I    [***]
	
 
	
 
	
 
	
[***]
	
[***]
	
[***]

	
1    [***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	

	
2    [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
II   [***]
	
 
	
 
	
 
	
[***]
	
[***]
	
[***]

	
1    [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]                                                                          [***]                                [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]                                                                          [***]                                [***]
	
[***]
	
[***]
	
[***]
	
[***]

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
2   [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]                                                                          [***]                                [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]                                                                          [***]                                [***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]                                                                          [***]                                [***]
	
[***]
	
[***]
	
[***]
	
[***]

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
3    [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]                                                                          [***]                                [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]                                                                          [***]                                [***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
4    [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 

	
1) [***]                                                               [***]                                [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
1) [***]                                                               [***]                                [***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 

	
1) [***]                                                               [***]                                [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	

	
1) [***]                                                               [***]                                [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 

	
1) [***]                                                               [***]                                [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
1) [***]                                                               [***]                                [***]
	
[***]
	
[***]
	
[***]
	
[***]

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
i) [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 

	
ii) [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 

	
iii) [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
iv) [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
v) [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
vi) [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
vii) [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
vii) [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
ix) [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
x) [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
xi) [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
xii) [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
4     [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]                                                                    [***]                               [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
III [***]
	
 
	
 
	
 
	
[***]
	
[***]
	
[***]

	
1    [***]
	
 
	
 
	
 
	
 
	
[***]
	
[***]

	
[***]                                                                    [***]                               [***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]                                                                    [***]                               [***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]                                                                    [***]                               [***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 

	
2    [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]                                                                    [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
 
	
 
	
 
	
 
	
 
	
 

	
3    [***]
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]                                                                    [***]                               [***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
IV [***]
	
 
	
 
	
 
	
[***]
	
[***]
	
[***]

	
V  [***]
	
 
	
 
	
 
	
[***]
	
[***]
	
[***]

	
Total [***]
	
 
	
 
	
 
	
[***]
	
[***]
	
[***]

 

 

		

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 35 of 44

 

	
Timeline
	
CONFIDENTIAL

	
[***]
	
 

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 36 of 44

 

 

		
	
Actual expenses
	
CONFIDENTIAL

 

Estimation Date: [***] 

Estimate [***]

 

Actual expenses

 

Actual expenses:

 

(1) [***]

1) [***] 

2) [***]

3) [***]

 

(2) [***]

1) [***]

2) [***]

 

(3) [***]

1) [***]

2) [***]

 

(4) [***]

[***]

[***]

 

(5) Others

1) [***]

2) [***]

3) [***]

 

(6) [***]

[***]

 

(7) [***]

[***]

 

(8) [***]

[***]

 

(9) [***]

[***]

 

 

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 37 of 44

 

APPENDIX H:  Investigator Payment Estimate Detail  

See attached budget on next page.

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 38 of 44

 

 

	
Sponsor
	
Coherus
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Protocol
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Date
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
Grand Total
	
[***]
	
 
	
 
	
 
	
 

	
Patient Costs 
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Country
	
[***]
	
[***]
	
[***]
	
Total
	
 
	
Country
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]

	
Total
	
 
	
 
	
[***]
	
[***]
	
 
	
TOTAL
	
[***]
	
[***]
	
[***]

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Patient Costs 
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***] 
	
[***]
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Country
	
[***]
	
[***]
	
[***]
	
Total
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

	
Total
	
 
	
 
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 39 of 44

 

 

	
Site Costs [***]
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 

	
Country
	
[***]
	
[***]
	
Total

	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]

	
Total
	
 
	
[***]
	
[***]

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 40 of 44

 

 

	
Sponsor
	
Coherus
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Protocol
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Date
	
[***]
	
 
	
 

	
 
	
 
	
[***]
	
[***]
	
 

	
Visit
	
Cost
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
Day
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***] 
	
[***]
	
[***]
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
[***]
	
 
	
[***]
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***] 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
Total [***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
Total  Study
	
 
	
[***]
	
 
	
 
	
 
	
 
	
 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 41 of 44

 

 

	
Sponsor
	
Coherus
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Protocol
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Date
	
[***]
	
 
	
 

	
 
	
 
	
[***]
	
[***]
	
 

	
Visit
	
Cost
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
Day
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 

	
[***] 
	
[***]
	
[***]
	
 
	
 
	
[***]
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
 
	
[***]
	
 
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
Total [***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
Total  Study
	
 
	
[***]
	
 
	
 
	
 
	
 
	
 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 42 of 44

 

 

													
	
 
	
 
	
[***]
	
[***]
	
 
	
 
	
 
	
 
	
[***]
	
[***]
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Country
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
Total

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 
	
[***]
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Country
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
Total
	
 
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
 
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
[***]
	
[***]
	
 
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

 

 

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 43 of 44

 

APPENDIX I:  [***]

The table below reflects [***] included in this Task Order.  Any [***] may require [***].

 

	
JobTitle
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

 

	
JobTitle
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]
	
[***]

 

 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

 

Medpace Task Order #23

 COHERUS BIOSCIENCES, INC

ETA305 

Page 44 of 44

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]